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Abstract
The N-termini of bacterial lipoproteins are acylated with a (S)-(2,3-bisacyloxypropyl)cysteinyl
residue. Lipopeptides derived from lipoproteins activate innate immune responses by engaging
Toll-like receptor 2 (TLR2), and are highly immunostimulatory and yet without apparent toxicity
in animal models. The lipopeptides may therefore be useful as potential immunotherapeutic
agents. Previous structure-activity relationships in such lipopeptides have largely been obtained
using murine cells and it is now clear that significant species-specific differences exist between
human and murine TLR responses. We have examined in detail the role of the highly conserved
Cys residue as well as the geometry and stereochemistry of the Cys-Ser dipeptide unit. (R)-
diacylthioglycerol analogues are maximally active in reporter gene assays using human TLR2.
The Cys-Ser dipeptide unit represents the minimal part-structure, but its stereochemistry was
found not to be a critical determinant of activity. The thioether bridge between the diacyl and
dipeptide units is crucial, and replacement by an oxoether bridge results in a dramatic decrease in
activity.
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Introduction
The link between immune stimulation resulting from acute infection and the resolution of
tumors has long been recognized,1 and the phenomenon of infection-related “spontaneous
regression” of cancer has been documented throughout history, beginning as early as 2600
B.C.2;3 The foundations of modern immunotherapy for cancer were laid in 1891 by William
B. Coley, who, in 1891, injected live streptococcal organisms into a long-bone sarcoma
lesion and observed shrinkage of the tumor.4 More than a century has elapsed since Coley’s
empirical findings were first reported, but the active principle(s) in Coley’s toxin remain
undetermined. This long lag-period is perhaps not altogether surprising because the
recognition of innate immune system is, in itself, recent,5–7 and our understanding of the
structure and function of the family of Toll-like receptors (TLRs)8;9 that recognize
“pathogen-associated molecular patterns (PAMPs)”,10 and the effector mechanisms that
mediate innate immune responses11–13 are yet nascent. Nonetheless, there exists
considerable potential in harnessing innate immune responses in a wide range of disease
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states, notably cancer, as evidenced by the number of TLR agonists already in clinical trials,
14 and the resurgence of interest in the immunotherapy of neoplastic states.15–17
The exoskeleton of the Gram-positive organism, similar to that of Gram-negative bacteria, is
comprised of underlying peptidoglycan (PGN), a polymer of β-1→4-linked N-
acetylglucosamine-N-acetylmuramic acid glycan strands that are cross-linked by short
peptides.18–20 Unlike Gram-negative bacteria which bear lipopolysaccharide on the outer
leaflet of the outer membrane, the external surface of the peptidoglycan layer is decorated
with lipoteichoic acids (LTA).21;22 LTA are anchored in the peptidoglycan substratum via a
diacylglycerol moiety and bear a surface-exposed, polyanionic, 1–3-linked
polyglycerophosphate appendage 23;24 which varies in its subunit composition in LTAs
from various Gram-positive bacteria; in S. aureus, the repeating subunit contains D-alanine
and α-D-N-acetylglucosamine25. Lipoproteins are found in the bacterial cytoplasmic
membrane and are also common constituents of the cell wall of both Gram-negative and
Gram-positive bacteria.25–27 The free amine of the N-terminus of lipoproteins is acylated
with a (S)-(2,3-bisacyloxypropyl)cysteinyl residue which has previously been demonstrated
to be immunostimulatory28;29 as shown by studies on synthetic peptides containing the bis-
acylthioglycerol unit.25;30;31 In contradistinction to enterobacterial LPS which is recognized
by Toll-like receptor-4 (TLR4), PGN, 32;33 LTA,34;35 lipopeptides,36;37 as well as some
non-enterobacterial LPS38;39 signal via TLR2.40;41
In comparing the various constituents of the Gram-positive cell wall, we have found
lipopeptides to be extremely potent TLR2 agonists, and yet without apparent toxicity in
animal models.42 In murine cells, PAM2CSK4 (S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-R-
cysteinyl-S-seryl-S-lysyl-S-lysyl-S-lysyl-S-lysine), a commercially-available, synthetic
model lipopeptide was equipotent in its NF-κB inducing activity relative to LPS, but elicited
much lower proinflammatory cytokines, while both LPS and the lipopeptide potently
induced the secretion of a similar pattern of chemokines suggestive of the engagement of
downstream TRIF pathways.42 Furthermore, we have found that while LPS, as expected,
elicited a robust fever response in rabbits at a dose of 100 ng/kg, a 200 μg/kg dose (2000 X)
of the lipopeptide was without any discernible pyrogenic or other apparent acute toxic effect
(manuscript in preparation). These observations suggest that the lipopeptides may be
remarkably potent, yet nontoxic immunotherapeutic agents. Indeed, in a Phase I/Phase II
clinical trial43 on a single, intraoperative 20–30 μg intratumoral injection of MALP-228 (a
diacyl lipopeptide similar in its core structure to PAM2CSK4) in patients with inoperable
carcinoma of the pancreas, the lipopeptide was well-tolerated and proved efficacious in
prolonging survival.43
Considerable structure-activity relationships dictating TLR2 binding and subsequent
stimulation of innate immune responses have been documented for a range of synthetic
lipopeptides. It should be pointed out, however, that the majority of earlier SAR studies had
been performed with murine cells, many even before the TLRs had been discovered, and it
is now clear that significant species-specific differences exist between human and murine
TLR responses36;44 as a consequence of subtle structural differences in the ligand binding
pocket within TLR2.45
The minimal structure for biological activity is the Cys-Ser lipodipeptide46 with the
lipoaminoacid Cys-OH derivative being almost inactive;47 the remainder of the peptidic unit
appears, in large part, not to be critical for activity since a variety of analogues of different
lengths with different amino acid sequences were found to be equipotent.46;48–50 The (R)-
configuration at the asymmetric glyceryl carbon confers maximum activity,30;51 and the
threshold of the acyl chain length of the two ester-bound fatty acids is 8 carbons, with
shorter acyl analogues being inactive.36 Furthermore, the recent high-resolution crystal
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structure of lipopeptides complexed to human- as well as murine-derived TLR1/TLR2
heterodimers45 raises additional questions since the binding site in TLR2 is highly unusual,
being located in the convex region formed at the border of the central and C-terminal
domains with the peptidic unit interacting with interfacial residues at the neck region of the
binding pocket.45 It was of interest to examine whether the chirality of the highly conserved
Cys residue (L-Cys versus D-Cys) and the thioether bridge connecting the diacylglycerol
unit to the peptide chain are critical determinants of activity, and if the thioether could be
bioisosterically substituted by an oxoether linkage. The geometry of the Cys-Ser dipeptide
unit also appears to be crucial, in that there are key interactions with conserved Tyr316 and
Pro315 residues at the neck of the binding pocket in the crystal structure.45 It is to be noted
that the carboxylic acid of Cys is in amide linkage with the amine of serine, and we wished
to test whether inversion of the orientation of Ser, achieved by the coupling the carboxyl
group of serine to the amino group of cysteamine could perhaps yield analogues that were
TLR2 receptor antagonists.
Results and Discussion
Much of the previous work in the literature concerning the structure-activity relationships in
lipopeptides have utilized murine TLR2, and in an effort to confirm the minimal part-
structure of the lipopeptide that was TLR-agonistic on human TLR2, we first targeted the
stereoselective syntheses of 1,2-dipalmitoyl (R)- and -(S)-3-(2-aminoethylthio)propanediol
(6a and 6b, Scheme 1) starting from the corresponding enantiopure 1,2-
isopropylideneglycerol. The (R)-cysteamine lipoamino acid 6a was weakly active (IC50: 1
μM, Fig. 1) relative to the commercially available reference lipopeptide PAM2CSK4 (IC50:
67 pM), while the (S)-analogue 6b was completely inactive. Coupling L-serine to the free
amine of the cysteamine resulted in the lipodipeptides 8a and 8b; similar to the cysteamine
analogues, only 8a was active with an IC50 of 1.2 μM; it is to be noted that in these latter
compounds, the dipeptide unit is inverted since, unlike in the naturally occurring as well as
in synthetic PAM2CSK4, it is the carboxyl group of the serine that is coupled to the
lipopeptide. The L-cysteine-containing lipoamino acid, compound 11 (Scheme 2) was also
found to be weakly TLR2-agonistic, which is in contradistinction to the virtually absent
activity on murine cells described earlier.47 The results emphasize differences in ligand
specificity between murine and human TLR2. The difference in activity between the R- and
S-isomers which was consistent with previous SAR results,30;51 served to focus our
subsequent SAR in which we elected to examine only the R-diacylthioglycerol analogues.
The PAM2Cys-Ser compounds of the 14 series comprising of combination of L- or D-
amino acids at either position, and with the carboxyl terminus as either the carboxylic acid
or the methyl ester (Scheme 2) were all highly active with the IC50 values in the mid-
picomolar range (Fig. 1), signifying that the stereochemistry of the dipeptide unit is non-
critical as long as the orientation of the amide bond is in the correct configuration as
discussed earlier. These results are consonant with the crystal structure of PAM2CSK4
complexed with TLR2, in which the carbonyl Cys-Ser amide bond forms H-bonding with
Pro315 and the NH of the amide interacts with Y326, but the side-chains of the dipeptide
unit show no significant van der Waals interactions within the binding pocket.45 The relative
unimportance of the side-chains of the dipeptide core are also in agreement with
observations that in naturally-occurring lipopeptides, the second amino acid is far less
conserved, and can be replaced by other residues with non-bulky side-chains such as Gly,
46;48–50 presumably as long as steric interactions within the narrow neck region of the
binding pocket45 are not compromised. While the PAM2CS methylester compounds are
indeed highly active, they are about a fifth as potent as the reference PAM2CSK4
lipopeptide. We have found that, as with other amphipathic compounds that we have
recently characterized,52 the apparent differences in potencies are related, at least in part, to
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the substantially higher binding of the more hydrophobic PAM2CS analogues to albumin
present in cell culture media, details of which will be published elsewhere.
It was of particular interest to examine the role of the thioether bridge between the diacyl
and dipeptide units. O-alkylation of R-1,2-isopropylideneglycerol with racemic ethyl 2,3-
ethoxypropanoate yielded the key intermediate 15, from which the oxoether-bridged
compounds were obtained (21a and 21b, Scheme 3) in which two of the three stereocenters
were held fixed. The activity of 21a (lipopeptide terminating with L-Ser) was about eight
orders of magnitude lower (IC50: 1.2 mM) than that of PAM2CSK4 while 21b (D-Ser) was
inactive at the highest concentration tested (10 mM; Fig. 1). While these results are
indicative of the absolute requirement of the thioether linkage, we do not yet understand
why the stereochemistry of the terminal Ser residue manifests in differential activity only in
the ether-linked (21a, 21b), but not in the thioether-linked analogues (14a-d).
We next tested whether the ester-linked palmitoyl groups could be replaced with potentially
hydrolytically more stable ether and amide linkages without compromising activity.
Synthesis of analogue 28 with the ether-linked C16 hydrocarbon appendages could not be
obtained by direct O-alkylation of an advanced intermediate such as the deprotected species
from series 12 under a variety of conditions. This necessitated the installation of the ether-
linked C16 groups on the glycerol backbone (23) first, followed by transformation of the free
hydroxyl to the iodo intermediate (25), and subsequent S-alkylation with cysteine (Scheme
4). We found that the ether analogue 28 was entirely inactive (Fig. 2).
We next investigated the bioisoteric replacement of one (internal, secondary alcohol-
derived; Scheme 5) ester as well as both the esters (Scheme 6) with amide-linked
hydrocarbon chains. Synthesis of the monoamide analogue 37 proceeded smoothly starting
from D-Ser-OMe (29). The diamide analogue, 45, however, was more problematic to
synthesize. Acetonide deprotection of the monoamide precursor 35, followed by attempts at
converting the free hydroxyl group to the amine via an azide intermediate was unsuccessful.
The strategy of first N-acylating (R) -methyl 2,3-diaminopropanoate with palmitoyl chloride,
and then converting the ester to the iodo via the alcohol as described in Scheme 5 was also
not fruitful because of unexpected difficulty in the conversion of the alcohol to the iodo
group. This is probably due either to steric bulk of the long-chain amides or to an internal H-
bond between the free alcohol and one of the amide groups. We therefore resorted to first
installing the iodo on a N, N′-di-Boc-protected 2,3-diaminopropane-1-ol, followed by S-
alkylation with N-Troc-L-Cys-OMe (Scheme 6), affording the required orthogonality of the
protecting groups The amines on the diaminopropane-thiol fragment of compound 41 were
then acylated with hexadecanoic acid. Next, the base-labile N-Troc protecting group on the
cysteine unit had to be converted to the N-Boc derivative in order to carry out subsequent
base-catalyzed de-esterfication step. Coupling of the terminal Ser residue proceeded
smoothly.
The monoamide derivative 37 was found to be partially active (IC50: 48 nM, Fig. 2),
although weaker by about three orders of magnitude compared to the reference lipopeptide
PAM2CSK4, while the diamide derivative 45 was completely inactive. The progressive loss
of activity from the monoamide to the diamide analogue suggests that both ester groups are
important for maximal TLR2-stimulatory activity, although this is yet to be formally tested
by synthesizing the regioisomer of 37 with the amide group replacing the external (primary
alcohol-derived) ester group.
We were also keen to test the possibility that some of the inactive compounds could perhaps
behave as TLR2 antagonists, particularly with 8a and 8b, since we had designed these
compounds with inverted cysteamine-serine amide bonds in the hope that this would be the
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case. It could be noted in this context that TLR2-mediated immunopathology has been
implicated in a number of inflammatory bowel diseases,53–56 and the only reported TLR2
receptor antagonists are rather weak lipolanthionine derivatives.57 Although we were
disappointed that 6a, 6b, 21a-b, 28, 37 and 45 were all inactive as TLR2 receptor
antagonists, the negative results add to the SAR data in that they demonstrate that these
compounds do not engage TLR2.
In addition to the lipopeptides being potentially useful as immunotherapeutic agents for
cancer, they also display potent adjuvant properties. Lipopeptides greatly enhance MHC
Class I-restricted CTL proliferation to an immunodominant influenza peptide Mx58-66 in a
human autologous DC/CD8+ T cell co-culture model.58 Lipopeptide-primed dendritic cells
also stimulate the proliferation of allogeneic naïve CD8+ CTLs,58 and immunization of mice
with influenza-specific peptide results in greatly enhanced numbers of interferon-γ-secreting
CD8+ CTLs when lipopeptides were used as adjuvants.59 Similarly, MALP-2 induces
robust, long-lived CTL responses against HIV-1 Tat protein.60;61 The synthetic methods that
we have developed are easily scalable, and the availability of a free amino group in
PAM2CS should allow the facile introduction of electrophilic labels such as isothiocyanate
for covalent coupling to vaccine antigens. Differential protein binding should also allow
considerable control of pharmacokinetic properties. These are currently being investigated.
Experimental Section
Chemistry
All of the solvents and reagents used were obtained commercially and used as such unless
noted otherwise. Moisture or air-sensitive reactions were conducted under argon atmosphere
in oven-dried (120°C) glass apparatus. Solvents were removed under reduced pressure using
standard rotary evaporators. Flash column chromatography was carried out using silica gel
635 (60–100 mesh), while thin-layer chromatography was carried out on silica gel CCM
pre-coated aluminum sheets. All yields reported refer to isolated material characterized
by 1H and 13C NMR, and mass spectrometry. Purity for all final compounds was confirmed
to be at least 97% by LC-MS using a Zorbax Eclipse Plus 4.6 × 150 mm, 5μ analytical
reverse phase C18 column with H2O-isopropanol and H2O-CH3CN gradients, and an Agilent
ESI-TOF mass spectrometer (mass accuracy: 3 ppm) operating in the positive ion
acquisition mode.
Syntheses of Compounds 2a ((R)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-
methylbenzenesulfonate and 2b ((S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 4-
methylbenzenesulfonate)
O-tosylation of (S)-(+)- [1a] and (R)-(-)-2,2-dimethyl-1,3-dioxolane-4-methanol [1b]. To
enantiopure (S)-(+)- or (R)-(−)-2,2-dimethyl-1,3-dioxolane-4-methano1 (compounds 1a and
1b, respectively, 1.0 g, 7.57 mmol, Sigma-Aldrich, Inc., St. Louis, MO) dissolved in
anhydrous DCM (30 mL) and cooled to 0 °C was added pyridine (1.22 mL, 15.14 mmol),
followed by p-toluenesulfonyl chloride (p-TsCl; 2.89 g, 22.70 mmol). The reaction solution
was brought to r.t. and stirred for 8 h. After removal of solvent under vacuum, the residue
was purified by flash column chromatography (hexane:EtOAc = 49:1) to afford the literature
compounds 2a (R) and 2b (S) in 96–98% yields.62;63
Syntheses of Compounds 3a ((R)-tert-butyl 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methylthio)
ethylcarbamate) and 3b ((S)-tert-butyl 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methylthio)
ethylcarbamate)
To a solution of 2a or 2b (800 mg, 2.80 mmol) in anhydrous DMF (15 mL) cooled to 0 °C
was added sodium hydride (NaH; 101 mg, 4.19 mmol). After stirring for 30 min at 0 °C, N-
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Boc-cysteamine (N-Boc-2-aminoethanethiol; 595 mg, 3.36 mmol) was added dropwise. The
reaction solution was then brought to r.t. and stirred for 8 h. After quenching unreacted NaH
with 1 M HCl, the solvent was removed under reduced pressure, and the residue was
dissolved in EtOAc and washed with water. The water layer was extracted thrice with
EtOAc. The combined organic layers were washed with brine and dried over Na2SO4. After
removal of solvent under reduced pressure, the residue was purified by flash column
chromatography (hexane:EtOAc = 5:1) to afford the title compounds 3a and 3b as colorless
oils (90–94%).
3a—1H NMR (400 MHz, CDCl3) δ 4.98 (d, J = 27.4, 1H), 4.22 (p, J = 6.2, 1H), 4.07 (dd, J
= 6.1, 8.3, 1H), 3.67 (dd, J = 6.4, 8.3, 1H), 3.35 (m, 2H), 2.78–2.58 (m, 4H), 1.41 (s, 9H),
1.40 (s, 3H), 1.32 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 155.78, 109.67, 79.48, 75.58,
68.82, 39.79, 33.01, 28.40, 26.90, 25.55. MS (ESI) calculated for C13H25NO4S, m/z 291.15,
found 292.16 (M+H)+ and 314.14 (M+Na) +.
3b—1H NMR (400 MHz, CDCl3) δ 4.92 (s, 1H), 4.23 (p, J = 6.2, 1H), 4.12–4.04 (m, 1H),
3.68 (dd, J = 6.4, 8.3, 1H), 3.31 (m, 2H), 2.79–2.58 (m, 4H), 1.43 (s, 9H), 1.41 (d, J = 0.4,
3H), 1.34 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 155.78, 109.65, 79.45, 75.57, 68.81,
39.80, 24.95, 32.98, 28.40, 26.89, 25.55. MS (ESI) calculated for C13H25NO4S, m/z 291.15,
found 292.15 (M+H)+ and 314.14 (M+Na+).
Syntheses of Compounds 4a ((R)-tert-butyl 2-(2,3-dihydroxypropylthio)ethylcarbamate)
and 4b ((S)-tert-butyl 2-(2,3-dihydroxypropylthio)ethylcarbamate)
Acetonide deprotection of compounds 3a and 3b (900 mg, 3.09 mmol) was achieved by
adding 70% acetic acid (AcOH:H2O = 7:3) and stirring at r.t. for 12 h. After removal of
solvent under vacuum, the reaction residue was dissolved in EtOAc, and washed with sat.
NaHCO3 solution. The aqueous layer was extracted thrice with EtOAc. The combined
EtOAc layers were washed with brine and dried over Na2SO4. After removal of solvent
under vacuum, the residue was purified by flash column chromatography (hexane:EtOAc =
3:1) to afford the title compounds 4a and 4b (88–91%).
4a—1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.3, 1H), 7.34 (d, J = 8.0, 1H), 4.93 (s, 1H),
3.85–3.75 (m, 1H), 3.70 (dt, J = 5.2, 10.3, 1H), 3.55 (dd, J = 5.9, 11.3, 1H), 3.31 (d, J = 5.3,
2H), 2.77–2.57 (m, 4H), 1.42 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 156.20, 79.80, 70.40,
65.26, 39.85, 35.53, 32.96, 28.40. MS (ESI) calculated for C10H21NO4S, m/z 251.12, found
252.13 (M+H)+ and 274.11 (M+Na)+.
4b—1H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 6.98 (s, 1H), 4.87 (s, 1H), 3.79 (ddd, J =
4.2, 6.9, 12.0, 1H), 3.75–3.68 (m, 1H), 3.55 (dt, J = 5.6, 11.3, 1H), 3.32 (d, J = 3.9, 2H),
2.78–2.55 (m, 4H), 1.43 (s, 9H). MS (ESI) calculated for C10H21NO4S, m/z 251.34, found
252.13 (M+H) + and 274.12 (M+Na) +.
Syntheses of Compounds 5a ((R)-3-(2-(tert-butoxycarbonylamino)ethylthio)propane-1,2-
diyl dipalmitate) and 5b ((S)-3-(2-(tert-butoxycarbonylamino)ethylthio)propane-1,2-diyl
dipalmitate)
O-palmitoylation of compounds 5a and 5b. To a solution of compound 4a and 4b (200 mg,
0.80 mmol) in anhydrous DCM (8 mL) at 0 °C were added pyridine (385 μL, 4.78 mmol)
and a catalytic amount of 4-(dimethylamino)pyridine (DMAP). Palmitoyl chloride (876 mg,
3.19 mmol) was then added dropwise and the reaction was brought to r.t., after which the
reaction solution was stirred for10 h. The reaction mixture was sequentially washed with
water, sat. NaHCO3, brine, and then dried over Na2SO4. After removal of solvent under
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vacuum, the residue was purified by flash column chromatography (hexane:EtOAc = 8:1) to
afford the title compounds 5a and 5b as white solids (90–92%).
5a—1H NMR (400 MHz, CDCl3) δ 5.12 (m, 1H), 4.88 (s, 1H), 4.34 (dd, J = 3.5, 11.9, 1H),
4.15 (dd, J = 6.0, 11.9, 1H), 3.30 (d, J = 6.1, 2H), 2.68 (dd, J = 6.5, 11.5, 4H), 2.38–2.24 (m,
4H), 1.62–1.54 (m, 4H), 1.42 (s, 9H), 1.25 (d, J = 10.6, 48H), 0.86 (t, J = 6.9, 6H). 13C
NMR (126 MHz, CDCl3) δ 173.42, 173.16, 155.77, 79.50, 70.30, 63.56, 39.59, 34.31,
34.12, 43.14, 31.94, 29.72, 29.69, 29.66, 29.61, 29.52, 29.46, 29.38, 29.31, 29.26, 29.15,
29.13, 29.09, 28.39, 24.91, 24.74, 22.71, 14.15. MS (ESI) calculated for C42H81NO6S, m/z
727.58, found 728.59 (M+H) + and 750.57 (M+Na) +.
5b—1H NMR (400 MHz, CDCl3) δ 5.12 (m, 1H), 4.88 (s, 1H), 4.34 (dd, J = 3.5, 11.9, 1H),
4.15 (dd, J = 6.0, 11.9, 1H), 3.30 (d, J = 6.1, 2H), 2.68 (dd, J = 6.4, 11.5, 4H), 2.34–2.25 (m,
4H), 1.64–1.56 (m, 4H), 1.42 (s, 9H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 6H). MS (ESI)
calculated for C42H81NO6S, m/z 727.58, found 728.59 (M+H) + and 750.57 (M+Na) +.
General procedure for N-Boc deprotection: Syntheses of Compounds 6a ((R)-3-(2-
aminoethylthio)propane-1,2-diyl dipalmitate) and 6b ((S)-3-(2-aminoethylthio)propane-1,2-
diyl dipalmitate)
To 5a and 5b was added excess dry trifluoroacetic acid (TFA) and stirred at r.t. for 30 min.
TFA was removed by purging nitrogen and the residue was thoroughly washed with diethyl
ether to obtain the title compounds as flaky white solids(98–100%).
6a—1H NMR (400 MHz, DMSO) δ 7.83 (s, 1H), 5.18–5.06 (m, 1H), 4.30 (dd, J = 2.7, 11.9,
1H), 4.10 (dd, J = 7.2, 12.0, 1H), 2.99 (t, J = 7.2, 2H), 2.90–2.65 (m, 4H), 2.32–2.14 (m,
4H), 1.58–1.42 (m, 4H), 1.23 (s, 48H), 0.84 (t, J = 6.8, 6H). 13C NMR (126 MHz, DMSO) δ
172.47, 172.29, 69.64, 63.47, 33.62, 33.53, 33.37, 31.29, 30.87, 29.06, 29.03, 29.01, 28.93,
28.75, 28.71, 28.50, 28.42, 28.38, 24.47, 24.38, 22.08, 13.91. MS (ESI) calculated for
C37H73NO4S, m/z 627.53, found 628.51 (M+H)+.
6b—1H NMR (400 MHz, DMSO) δ 7.80 (s, 1H), 5.16–5.05 (m, 1H), 4.30 (dd, J = 2.8, 11.9,
1H), 4.10 (dd, J = 7.1, 12.0, 1H), 2.99 (t, J = 7.1, 2H), 2.87–2.65 (m, 4H), 2.33–2.20 (m,
4H), 1.50 (d, J = 6.2, 4H), 1.23 (s, 48H), 0.84 (t, J = 6.8, 6H). MS (ESI) calculated for
C37H73NO4S, m/z 627.53, found 628.51 (M+H)+.
Syntheses of Compounds 7a ((6 R,13R)-6-(hydroxymethyl)-2,2-dimethyl-4,7-dioxo-3-
oxa-11-thia-5,8-diazatetradecane-13,14-diyl dipalmitate) and 7b ((6S,13R)-6-
(hydroxymethyl)-2,2-dimethyl-4,7-dioxo-3-oxa-11-thia-5,8-diazatetradecane-13,14-diyl
dipalmitate)
The terminal L-serine of the dipeptide unit was appended to 6a and 6b by conventional
solution phase coupling procedures. To 6a and 6b (200 mg, 0.27 mmol) in anhydrous DCM
(8 mL) at 0 °C were added Boc-L-Ser-OH (Bachem Americas, Inc., Torrance, CA, 83 mg,
0.40 mmol), (3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI; 103 mg,
0.54 mmol), N, N-diisopropylethylamine (EDIPA; 53.4 μL, 0.32 mmol), and a catalytic
amount of DMAP. The reaction mixture was stirred at 0 °C for 30 min, and then brought to
r.t., and stirred for an additional 8 h. After removal of solvent under vacuum, the residue was
purified by flash column chromatography (hexane:EtOAc = 3:2) to afford the title
compounds 7a or 7b as white solids (75–80%).
7a—1H NMR (400 MHz, CDCl3) δ 6.92 (s, 1H), 5.54 (s, 1H), 5.11 (dt, J = 5.0, 9.8, 1H),
4.36 (dd, J = 3.3, 11.9, 1H), 4.16–4.04 (m, 3H), 3.64 (s, 1H), 3.56–3.37 (m, 2H), 2.90 (s,
1H), 2.77–2.61 (m, 4H), 2.29 (td, J = 4.5, 7.5, 4H), 1.58 (s, 4H), 1.44 (s, 9H), 1.23 (s, 48H),
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0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 172.30, 172.13, 170.33, 154.96, 79.32,
69.11, 62.38, 61.73, 53.57, 37.04, 33.11, 32.90, 31.01, 30.72, 28.50, 28.46, 28.44, 28.29,
28.16, 28.09, 27.92, 27.10, 23.68, 21.49, 12.92. MS (ESI) calculated for C45H86N2O8S, m/z
814.61, found 837.56 (M+Na) +.
7b—1H NMR (400 MHz, CDCl3) δ 6.91 (s, 1H), 5.53 (s, 1H), 5.12 (qd, J = 3.4, 6.5, 1H),
4.35 (dd, J = 3.4, 11.9, 1H), 4.16–4.03 (m, 3H), 3.64 (s, 1H), 3.57–3.34 (m, 2H), 2.91 (s,
1H), 2.78–2.61 (m, 4H), 2.29 (td, J = 4.1, 7.6, 4H), 1.60 (s, 4H), 1.44 (s, 9H), 1.23 (s, 48H),
0.86 (t, J = 6.8, 6H). MS (ESI) calculated for C45H86N2O8S, m/z 814.61, found 837.56 (M
+Na) +.
Syntheses of Compounds 8a ((R)-3-(2-((R)-2-amino-3-
hydroxypropanamido)ethylthio)propane-1,2-diyl dipalmitate) and 8b ((S)-3-(2-((R)-2-
amino-3-hydroxypropanamido)ethylthio)propane-1,2-diyl dipalmitate)
7a and 7b were deprotected with TFA as described earlier in the general procedure for N-
Boc deprotection (see syntheses of 6a, 6b). The title compounds were obtained as flaky
white solids(99–100%).
8a—1H NMR (400 MHz, DMSO) δ 8.51 (t, J = 5.7, 1H), 8.08 (s, 1H), 5.47 (s, 1H), 5.08
(dd, J = 4.5, 11.4, 1H), 4.31 (dd, J = 2.7, 11.9, 1H), 4.10 (dd, J = 7.1, 12.0, 1H), 3.69 (dd, J
= 9.1, 33.4, 3H), 3.28 (dd, J = 6.5, 13.3, 2H), 2.74 (ddd, J = 6.6, 14.1, 21.4, 2H), 2.62 (t, J =
6.9, 2H), 2.32–2.19 (m, 4H), 1.56–1.45 (m, 4H), 1.23 (s, 48H), 0.85 (t, J = 6.8, 6H). 13C
NMR (126 MHz, DMSO) δ 172.50, 172.27, 166.69, 69.88, 63.45, 60.27, 54.35, 38.52,
33.55, 33.37, 31.28, 31.04, 30.80, 29.05, 29.02, 29.00, 28.92, 28.91, 28.74, 28.71, 28.70,
28.41, 28.36, 24.47, 24.39, 22.08, 13.92. MS (ESI) calculated for C40H78N2O6S, m/z
714.56, found 715.54 (M+H) +.
8b—1H NMR (400 MHz, DMSO) δ 8.51 (t, J = 5.4, 1H), 8.08 (s, 1H), 5.48 (s, 1H), 5.09 (d,
J = 5.8, 1H), 4.30 (dd, J = 2.6, 11.9, 1H), 4.10 (dd, J = 7.1, 11.9, 1H), 3.85–3.57 (m, 3H),
3.32–3.26 (m, 2H), 2.80 (dd, J = 5.8, 14.1, 1H), 2.65 (ddd, J = 7.0, 13.9, 20.3, 3H), 2.31–
2.22 (m, 4H), 1.50 (d, J = 6.8, 4H), 1.23 (s, 48H), 0.84 (t, J = 6.7, 6H). 13C NMR (126 MHz,
DMSO) δ 172.85, 172.63, 167.10, 70.25, 63.84, 60.65, 54.71, 38.92, 33.92, 33.75, 31.66,
31.42, 31.17, 29.44, 29.41, 29.39, 29.30, 29.13, 29.10, 29.09, 28.80, 28.75, 24.80, 22.46,
14.18. MS (ESI) calculated for C40H78N2O6S, m/z 714.56, found 715.54 (M+H) +.
Synthesis of Compound 9 ((R)-4-(iodomethyl)-2,2-dimethyl-1,3-dioxolane)
To a solution of (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (compound 1a, 3.0 g, 22.70
mmol) in toluene (50 mL) was added triphenylphosphine (PPh3; 37.15 g, 27.38 mmol),
imidazole (4.64 g, 68.10 mmol) and iodine (7.0 g, 29.51 mmol).64 The reaction mixture was
stirred at 90 °C for 2 h. After removal of toluene under reduced pressure, the residue was
dissolved in DCM, washed with sat. Na2S2O3 (to quench the unreacted iodine), brine, and
dried over Na2SO4. The solvent was then removed under vacuum and the residue was
purified by flash column chromatography (hexane:EtOAc = 49:1) to afford the literature
compound 965 as a colorless liquid (5.44 g, 99%).
9—1H NMR (400 MHz, CDCl3) δ 4.30–4.21 (m, 1H), 4.12 (dd, J = 6.1, 8.6, 1H), 3.76 (dd,
J = 5.4, 8.6, 1H), 3.23 (dd, J = 4.6, 9.8, 1H), 3.12 (dd, J = 8.5, 9.8, 1H), 1.43 (s, 1H), 1.32 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 109.47, 74.63, 68.57, 26.11, 24.57, 5.67.
Wu et al. Page 8













Syntheses of Compounds 10a ((R)-methyl 2-(tert-butoxycarbonylamino)-3-(((R)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylthio)propanoate) and 10b ((S)-methyl 2-(tert-
butoxycarbonylamino)-3-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methylthio)propanoate)
N-Boc protected L- and D- cysteine methyl esters were first obtained by treating H-L- and
D-Cys-OMe3HCl (Sigma-Aldrich) with di-tert-butyl dicarbonate (Boc2O; 2.0 eq.) in DCM,
followed by slow addition of triethylamine (TEA; 1.0 eq.) at 0 °C. DCM was removed under
vacuum after the reaction was stirred at 0 °C for 2 h and the residue was then purified by
flash column chromatography with 10% EtOAc/hexane.) S-alkylation of Boc-L-Cys-OMe
and Boc-D-Cys-OMe with 9 were then carried out. Compound 10 was synthesized as
follows: to a solution of 9 (900 mg, 3.72 mmol) in anhydrous DMF (8 mL) was added TEA
(1.55 mL, 11.15 mmol), followed by Boc-L- or D-Cys-OMe (673 mg, 2.86 mmol). The
reaction solution was stirred at 85 °C for 4 h. After removal of DMF under vacuum, the
residue was purified by flash column chromatography (hexane:EtOAc = 9:1) to afford 10a
or 10b, respectively as viscous oils (60–63%).
10a—1H NMR (400 MHz, CDCl3) δ 5.39 (d, J = 7.1, 1H), 4.52 (d, J = 7.3, 1H), 4.21 (p, J =
6.2, 1H), 4.06 (dd, J = 6.1, 8.3, 1H), 3.74 (s, 3H), 3.66 (dd, J = 6.4, 8.3, 1H), 3.02 (d, J =
3.2, 2H), 2.73 (dd, J = 6.0, 13.4, 1H), 2.62 (dd, J = 6.5, 13.4, 1H), 1.43 (s, 9H), 1.40 (s, 3H),
1.33 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.49, 155.23, 109.73, 80.18, 75.64, 68.68,
53.45, 52.58, 38.78, 35.22, 28.31, 26.84, 25.55. MS (ESI) calculated for C15H27NO6S, m/z
349.16, found 372.10 (M+Na) +.
10b—1H NMR (400 MHz, CDCl3) δ 5.43 (d, J = 7.0, 1H), 4.52 (s, 1H), 4.26–4.18 (m, 1H),
4.06 (dd, J = 6.1, 8.3, 1H), 3.76 (d, J = 11.0, 3H), 3.66 (dd, J = 6.5, 8.3, 1H), 3.02 (ddd, J =
5.2, 13.8, 19.4, 2H), 2.75 (dd, J = 5.9, 13.5, 1H), 2.63 (dd, J = 6.3, 13.5, 1H), 1.43 (s, 9H),
1.41 (s, 3H), 1.34 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 171.49, 155.23, 109.73, 80.18,
75.64, 68.68, 53.45, 52.58, 35.78, 35.22, 28.31, 26.84, 25.55. MS (ESI) calculated for
C15H27NO6S, m/z 349.16, found 372.10 (M+Na) +.
General procedure for acetonide deprotection and palmitoylation of the 1,2-
isopropylideneglycerol unit: Synthesis of Compound11 ((R)-3-((R)-2-amino-3-methoxy-3-
oxopropylthio)propane-1,2-diyl dipalmitate)
To 10a (200 mg, 0.57 mmol) was added 15 mL of 70% acetic acid (AcOH:H2O = 7:3) and
the reaction was stirred at r.t. for 24h. After complete removal of AcOH and water under
reduced pressure, O-palmitoylation of the diol was carried out by sequential addition of
pyridine (278 μL, 3.44 mmol), a catalytic amount of DMAP, followed by palmitoyl chloride
(709 μL, 2.29 mmol) to the diol dissolved in anhydrous DCM (15 mL) and precooled to 0
°C. After stirring at 0 °C for 30 min, the reaction solution was brought to r.t. and stirred for
8 h. After removal of solvent under vacuum, the residue was purified by flash column
chromatography (hexane:EtOAc = 19:1) to afford the N-Boc-protected intermediate as a
colorless oil. Finally, N-Boc deprotection was carried out as described earlier (see syntheses
of 6a, 6b) to obtain the title compound 11 as a white glassy solid (435 mg, 95%). 1H NMR
(400 MHz, CDCl3) δ 8.01 (s, 2H), 5.13 (s, 1H), 4.41–4.06 (m, 3H), 3.81 (s, 3H), 3.20 (d, J =
41.1, 2H), 2.74 (s, 2H), 2.29 (dd, J = 7.9, 15.5, 4H), 1.58 (d, J = 4.7, 4H), 1.23 (s, 48H), 0.86
(t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 173.66, 173.63, 168.19, 69.95, 63.47, 53.73,
52.50, 34.24, 34.02, 32.91, 32.46, 31.94, 29.72, 29.70, 29.68, 29.52, 29.38, 29.30, 29.13,
24.85, 22.70, 14.13. MS (ESI) calculated for C39H75NO6S, m/z 685.53, found 686.59 (M
+H) +.
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General Procedure for de-esterification of 10a and 10b, and subsequent coupling of
serine: Syntheses of Compounds 12a-d
10a and 10b were de-esterified with aqueous LiOH (165 mg, 6.87 mmol dissolved in 6mL
water/15 mL THF) at r.t. for 10h. 1 M HCl solution was then added (to quench unreacted
LiOH and to convert the lithium salt to the free-acid form) until a pH of 4 was reached.
After removal of THF under vacuum, the residue was extracted thrice with DCM. The
combined DCM layers were washed with brine and dried over Na2SO4. After removal of
DCM under vacuum, H-L-Ser(tBu)-OtBu·HCl, or H-L-Ser(tBu)- OMe·HCl, or H-D-
Ser(tBu)-OMe·HCl (all from Bachem Americas, Inc., Torrance, CA, 437 mg, 2.06 mmol)
were coupled to the de-esterified intermediates as described earlier for the syntheses of 7a
and 7b. After removal of solvent under vacuum, the residue was purified by flash column




(400 MHz, CDCl3) δ 7.31 (s, 1H), 5.48 (s, 1H), 4.70–4.47 (m, 2H), 4.38–4.22 (m, 2H), 4.07
(dd, J = 6.1, 8.2, 1H), 3.79–3.71 (m, 1H), 3.67 (dd, J = 6.6, 8.2, 1H), 3.59–3.45 (m, 1H),
3.10 (d, J = 6.5, 1H), 2.96 (ddd, J = 6.1, 13.9, 43.9, 1H), 2.74 (ddd, J = 6.1, 13.5, 44.1, 1H),
1.43 (s, 18H), 1.33 (s, 3H), 1.22 (s, 3H), 1.11 (d, J = 4.0, 9H). MS (ESI) calculated for
C25H46N2O8S, m/z 534.30, found 557.29 (M+Na) +.
12b ((S)-methyl 3-tert-butoxy-2-((R)-2-(tert-butoxycarbonylamino)-3-(((R)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylthio)propanamido)propanoate)—1H NMR
(400 MHz, CDCl3) δ 7.07 (d, J = 8.3, 1H), 5.48 (s, 1H), 4.71–4.59 (m, 1H), 4.41–4.22 (m,
2H), 4.15–4.02 (m, 1H), 3.80 (dd, J = 2.9, 9.1, 1H), 3.72 (s, 3H), 3.68 (dd, J = 6.5, 8.3, 1H),
3.55 (dd, J = 3.2, 9.1, 1H), 3.06 (ddd, J = 5.9, 12.2, 19.8, 1H), 2.98–2.87 (m, 1H), 2.85–2.76
(m, 1H), 2.71 (dt, J = 6.8, 13.5, 1H), 1.44 (s, 9H), 1.42 (s, 3H), 1.34 (s, 3H), 1.12 (s,
9H). 13C NMR (126 MHz, CDCl3) δ 170.47, 170.41, 155.28, 109.70, 75.70, 74.81, 73.52,
68.73, 61.69, 54.10, 53.12, 52.43, 35.61, 35.22, 28.31, 27.30, 26.87, 25.56. MS (ESI)
calculated for C22H40N2O8S, m/z 492.25, found 515.18 (M+Na) +.
12c ((R)-methyl 3-tert-butoxy-2-((R)-2-(tert-butoxycarbonylamino)-3-(((R)-2,2-
dimethyl-1,3-dioxolan-4-yl)methylthio)propanamido)propanoate)—1H NMR
(400 MHz, CDCl3) δ 7.19 (s, 1H), 5.55 (s, 1H), 4.71 (d, J = 8.2, 1H), 4.39 (s, 1H), 4.35–4.25
(m, 1H), 4.16–4.08 (m, 1H), 3.85 (d, J = 9.0, 1H), 3.76 (s, 3H), 3.70 (t, J = 7.3, 1H), 3.57 (d,
J = 9.0, 1H), 3.13 (d, J = 15.0, 1H), 2.93 (dd, J = 6.1, 13.9, 1H), 2.86–2.71 (m, 2H), 1.48 (s,
9H), 1.45 (s, 3H), 1.38 (s, 3H), 1.15 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 170.60, 170.34,
155.39, 109.70, 75.52, 74.79, 73.50, 68.68, 61.75, 53.99, 52.86, 52.41, 35.51, 30.95, 28.31,




(400 MHz, CDCl3) δ 7.07 (d, J = 8.3, 1H), 5.48 (s, 1H), 4.71–4.59 (m, 1H), 4.41–4.22 (m,
2H), 4.15–4.02 (m, 1H), 3.80 (dd, J = 2.9, 9.1, 1H), 3.72 (s, 3H), 3.68 (dd, J = 6.5, 8.3, 1H),
3.55 (dd, J = 3.2, 9.1, 1H), 3.06 (ddd, J = 5.9, 12.2, 19.8, 1H), 2.98–2.87 (m, 1H), 2.85–2.76
(m, 1H), 2.71 (dt, J = 6.8, 13.5, 1H), 1.44 (s, 9H), 1.42 (s, 3H), 1.34 (s, 3H), 1.12 (s, 9H).
MS (ESI) calculated for C22H40N2O8S, m/z 492.25, found 515.18 (M+Na) +.
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Syntheses of Compounds 13a-d
Acetonide deprotection followed by O-palmitoylation of 12a-d were performed as per the
general procedure outlined earlier (synthesis of compound 11) to afford the corresponding
compounds 13a-d in 90–95% yields.
13a ((R)-3-((R)-2-(tert-butoxycarbonylamino)-3-((S)-1,3-di-tert-butoxy-1-
oxopropan-2-ylamino)-3-oxopropylthio)propane-1,2-diyl dipalmitate)—1H NMR
(400 MHz, CDCl3) δ 7.02 (d, J = 7.9, 1H), 5.37 (s, 1H), 5.19–5.09 (m, 1H), 4.51 (dt, J = 2.9,
8.0, 1H), 4.31 (dd, J = 3.5, 11.9, 2H), 4.14 (dd, J = 5.9, 11.9, 1H), 3.76 (dd, J = 2.9, 8.8,
1H), 3.51 (dd, J = 3.0, 8.8, 1H), 2.93 (d, J = 6.2, 2H), 2.79 (d, J = 6.1, 2H), 2.30 (ddd, J =
5.8, 10.8, 12.0, 4H), 1.59 (dd, J = 6.6, 12.8, 5H), 1.43 (d, J = 2.6, 17H), 1.23 (s, 48H), 1.12
(d, J = 2.6, 9H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 173.40, 173.13,
170.13, 168.92, 81.97, 73.17, 70.32, 63.52, 61.97, 53.51, 35.61, 34.31, 34.11, 33.71, 33.13,
31.94, 29.72, 29.68, 29.66, 29.53, 29.38, 29.33, 29.32, 29.16, 29.15, 28.30, 28.02, 27.34,




NMR (400 MHz, CDCl3) δ 7.06 (d, J = 8.1, 1H), 5.17 (s, 1H), 4.69–4.58 (m, 1H), 4.31 (dd,
J = 3.5, 11.9, 2H), 4.15 (dd, J = 5.9, 11.9, 1H), 3.80 (dd, J = 3.0, 9.1, 1H), 3.72 (s, 3H), 3.55
(dd, J = 3.2, 9.1, 1H), 2.94 (d, J = 6.1, 2H), 2.79 (d, J = 5.9, 2H), 2.29 (td, J = 4.9, 7.5, 4H),
1.59 (s, 4H), 1.43 (s, 9H), 1.23 (s, 48H), 1.12 (s, 9H), 0.86 (t, J = 6.8, 6H). 13C NMR (126
MHz, CDCl3) δ 173.37, 173.14, 170.44, 170.30, 155.22, 73.51, 70.29, 63.49, 61.67, 53.14,
52.41, 35.52, 34.30, 34.09, 33.20, 31.93, 29.71, 29.51, 29.37, 29.32, 29.31, 29.15, 29.14,
28.29, 27.29, 24.90, 24.88, 22.70, 14.13. MS (ESI) calculated for C51H96N2O10S, m/z
928.68, found 951.57 (M+Na) +.
13c ((R)-3-((R)-3-((R)-3-tert-butoxy-1-methoxy-1-oxopropan-2-ylamino)-2-(tert-
butoxycarbonylamino)-3-oxopropylthio)propane-1,2-diyl dipalmitate)—1H
NMR (400 MHz, CDCl3) δ 7.15–7.06 (m, 1H), 5.19–5.11 (m, 1H), 4.65 (d, J = 8.4, 1H),
4.31 (dd, J = 3.6, 11.9, 2H), 4.14 (dd, J = 5.9, 11.9, 1H), 3.81 (dd, J = 2.9, 9.0, 1H), 3.72 (s,
3H), 3.53 (dd, J = 3.3, 9.0, 1H), 2.94 (dd, J = 14.0, 20.2, 2H), 2.78 (s, 2H), 2.29 (dd, J = 7.5,
13.4, 4H), 1.59 (d, J = 6.7, 4H), 1.44 (s, 9H), 1.23 (s, 47H), 1.12 (d, J = 1.9, 9H), 0.86 (t, J =
6.9, 6H). 13C NMR (126 MHz, CDCl3) δ 173.76, 172.63, 171.22, 170.29, 73.10, 70.42,
63.59, 55.56, 52.96, 34.36, 34.05, 31.93, 30.96, 29.73, 29.68, 29.61, 29.55, 29.38, 29.32,
29.15, 19.12, 24.84, 22.70, 14.13. MS (ESI) calculated for C51H96N2O10S, m/z 928.68,
found 951.57 (M+Na) +.
13d ((R)-3-((S)-3-((S)-3-tert-butoxy-1-methoxy-1-oxopropan-2-ylamino)-2-(tert-
butoxycarbonylamino)-3-oxopropylthio)propane-1,2-diyl dipalmitate)—1H
NMR (400 MHz, CDCl3) δ 7.06 (d, J = 8.1, 1H), 5.17 (s, 1H), 4.69–4.58 (m, 1H), 4.31 (dd,
J = 3.5, 11.9, 2H), 4.15 (dd, J = 5.9, 11.9, 1H), 3.80 (dd, J = 3.0, 9.1, 1H), 3.72 (s, 3H), 3.55
(dd, J = 3.2, 9.1, 1H), 2.94 (d, J = 6.1, 2H), 2.79 (d, J = 5.9, 2H), 2.29 (td, J = 4.9, 7.5, 4H),
1.59 (s, 4H), 1.43 (s, 9H), 1.23 (s, 48H), 1.12 (s, 9H), 0.86 (t, J = 6.8, 6H). MS (ESI)
calculated for C51H96N2O10S, m/z 928.68, found 951.57 (M+Na) +.
General Procedure for one-step deprotection of N-Boc and O-tBu: Syntheses of
Compounds 14a-d
13a-d were deprotected with dry TFA as described earlier (general procedure for N-Boc
deprotection) which allowed for the simultaneous deprotection of the N-Boc and O-tBu
groups. Consequently, 14a was obtained as the –Ser-OH (free acid), while 14b-d were the –
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Ser-OMe esters. All title compounds (14a-d) were obtained as white glassy solids in near-
quantitative yields.
14a ((S)-2-((R)-2-amino-3-((R)-2,3-bis(palmitoyloxy)propylthio)propanamido)-3-
hydroxypropanoic acid)—1H NMR (400 MHz, DMSO) δ 9.10 (d, J = 7.4, 1H), 8.82 (d,
J = 7.9, 1H), 8.23 (s, 1H), 5.16 (d, J = 7.5, 1H), 4.81–4.58 (m, 1H), 4.42–4.23 (m, 2H),
4.18–4.07 (m, 1H), 3.79 (dd, J = 4.8, 11.0, 1H), 3.70–3.58 (m, 1H), 3.07 (dt, J = 6.7, 13.0,
1H), 2.94–2.65 (m, 3H), 2.31–2.13 (m, 4H), 1.55–1.44 (m, 4H), 1.22 (s, 48H), 0.84 (t, J =
6.7, 6H). 13C NMR (126 MHz, DMSO) δ 179.71, 177.74, 177.51, 176.39, 74.88, 68.75,
66.29, 60.04, 56.60, 38.87, 38.78, 38.61, 38.23, 36.53, 34.30, 34.25, 34.20, 34.17, 34.13,
34.03, 33.98, 33.95, 33.76, 33.68, 33.63, 29.71, 29.62, 27.32, 19.16. MS (ESI) calculated for
C41H78N2O8S, m/z 758.55, found 759.66 (M+H) +.
14b ((R)-3-((R)-2-amino-3-((S)-3-hydroxy-1-methoxy-1-oxopropan-2-ylamino)-3-
oxopropylthio)propane-1,2-diyl dipalmitate)—1H NMR (500 MHz, CDCl3) δ 8.21 (s,
1H), 5.28 (s, 1H), 5.20–5.07 (m, 1H), 4.79–4.60 (m, 2H), 4.47–4.26 (m, 2H), 4.14–4.04 (m,
1H), 3.99–3.90 (m, 1H), 3.74 (s, 3H), 3.24–2.97 (m, 2H), 2.75 (s, 2H), 2.36–2.23 (m, 4H),
1.57 (s, 4H), 1.23 (s, 48H), 0.86 (t, J = 7.0, 6H). 13C NMR (126 MHz, CDCl3) δ 174.39,
173.97, 169.90, 70.27, 70.08, 63.65, 63.52, 61.90, 52.92, 34.32, 34.05, 31.93, 29.73, 29.68,
29.55, 59.53, 29.38, 29.0, 29.14, 29.11, 24.89, 24.86, 24.82, 22.70, 14.12. MS (ESI)
calculated for C42H80N2O8S, m/z 772.56, found 773.53 (M+H)+.
14c ((R)-3-((R)-2-amino-3-((R)-3-hydroxy-1-methoxy-1-oxopropan-2-ylamino)-3-
oxopropylthio)propane-1,2-diyl dipalmitate)—1H NMR (400 MHz, CDCl3) δ 8.86–
8.37 (m, 1H), 5.40–5.22 (m, 1H), 5.21–5.01 (m, 1H), 4.72–4.42 (m, 2H), 4.42–4.16 (m, 2H),
4.08 (s, 1H), 4.01–3.88 (m, 1H), 3.73 (s, 3H), 3.39–2.98 (m, 2H), 2.73 (s, 2H), 2.29 (s, 4H),
1.56 (s, 4H), 1.23 (s, 48H), 0.85 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 174.22,
173.92, 70.02, 69.83, 63.66, 63.60, 53.02, 34.30, 34.05, 31.94, 29.73, 29.69, 29.56, 29.55,
29.39, 29.32, 29.16, 29.13, 24.88, 24.83, 22.70, 14.13. MS (ESI) calculated for
C42H80N2O8S, m/z 772.56, found 773.53 (M+H)+.
14d ((R)-3-((S)-2-amino-3-((S)-3-hydroxy-1-methoxy-1-oxopropan-2-ylamino)-3-
oxopropylthio)propane-1,2-diyl dipalmitate)—1H NMR (400 MHz, CDCl3) δ 8.74 (s,
1H), 7.87 (s, 1H), 5.32 (s, 1H), 5.13 (s, 1H), 4.46 (d, J = 80.5, 3H), 4.13 (s, 1H), 3.99 (s,
2H), 3.78 (s, 3H), 3.23 (s, 2H), 2.78 (s, 2H), 2.33 (s, 4H), 1.61 (s, 4H), 1.61 (s, 3H), 1.27 (s,
48H), 0.89 (t, J = 6.7, 6H). 13C NMR (126 MHz, CDCl3) δ 174.49, 173.76, 70.42, 63.59,
55.56, 53.70, 52.96, 48.56, 34.36, 34.05, 31.93, 29.73, 29.68, 29.55, 29.38, 29.32, 29.15,
29.12, 24.84, 22.70, 14.13. MS (ESI) calculated for C42H80N2O8S, m/z 772.56, found
773.53 (M+H)+.
Synthesis of compound 15 (ethyl 3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-
hydroxypropanoate)
To a solution of ethyl-2,3-epoxypropanoate (Sigma-Aldrich, Inc., 375 mg, 2.91 mmol) in
anhydrous DCM (10 mL) was added boron trifluoride diethyl etherate (BF3•OEt2; 83 mg,
0.58 mmol), followed by (S)-(+)- 2,2-dimethyl-1,3-dioxolane-4-methanol (1a, 1.20 g, 8.72
mmol).66 The reaction mixture was stirred at r.t. for 5 h. After removal of solvent under
reduced pressure, a mixture of ethyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-
hydroxypropanoate (compound 15) and (S)-(+)- 2,2-dimethyl-1,3-dioxolane-4-methanol
(unreacted starting material, 1a) were obtained. The Rf values of both the required product
as well as the starting material were identical which presented difficulty in chromatographic
isolation. The mixture was therefore subjected to selective protection of the primary
hydroxyl group of the acetonide-protected glycerol 1a with TBDMSCl (tert-
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butyldimethylsilyl chloride), which allowed the facile isolation of compound 15 by flash
column chromatography using 20% EtOAc/hexane (433 mg, 60%). 1H NMR (400 MHz,
CDCl3) δ 4.34–4.22 (m, 4H), 4.05 (dd, J = 6.4, 8.3, 1H), 3.88–3.80 (m, 2H), 3.75 (ddd, J =
6.3, 7.5, 8.2, 1H), 3.66–3.52 (m, 2H), 3.15 (dd, J = 6.6, 15.6, 1H), 1.44–1.27 (m, 9H). 13C
NMR (126 MHz, CDCl3) δ 171.49, 171.44, 108.42, 73.59, 73.55, 72.11, 72.04, 71.56,
69.95, 69.85, 65.57, 65.54, 60.85, 28.68, 25.68, 25.67, 24.37, 24.33, 13.17. MS (ESI)
calculated for C11H10O6, m/z 248.13, found 271.12 (M+Na+) and 519.245(M+M+Na) +.
Synthesis of compound 16 (ethyl 3-(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-2-
tosyloxy)propanoate)
O-tosylation was performed by sequentially adding TEA (590 μL, 4.23 mmol) and p-TsCl
(806 mg, 4.23 mmol) to a solution of 15 (350 mg, 1.41 mmol) in anhydrous DCM (10 mL)
cooled to 0 °C. The reaction mixture was brought to r.t. and stirred for 8 h. After removal of
solvent under vacuum, the residue was purified by flash column chromatography
(hexane:EtOAc = 9:1) to afford the title compound 16 (443 mg, 78%). 1H NMR (400 MHz,
CDCl3) δ 7.80 (d, J = 8.4, 2H), 7.31 (d, J = 8.0, 2H), 5.02–4.96 (m, 1H), 4.18–4.06 (m, 3H),
3.96–3.77 (m, 3H), 3.62 (ddd, J = 3.4, 6.3, 8.4, 1H), 3.54–3.38 (m, 2H), 2.42 (s, 3H), 1.35
(s, 3H), 1.31 (s, 3H), 1.19 (t, J = 7.1, 3H). 13C NMR (126 MHz, CDCl3) δ 165.34, 143.94,
132.12, 132.09, 128.55, 126.92, 108.23, 108.20, 75.73, 73.22, 71.20, 69.59, 65.31, 60.90,
25.48, 24.18, 20.49, 12.77. MS (ESI) calculated for C18H26O8, m/z 402.13, found 425.13 (M
+Na) +.
Synthesis of compound 17 (ethyl 2-azido-3-(((S)-2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy)propanoate)
To a solution of compound 16 (380 mg, 0.94 mmol) in anhydrous DMF (10 mL) was added
sodium azide (184 mg, 2.83 mmol). The reaction mixture was stirred at r.t. for 12 h. After
removal of DMF under vacuum, the reaction residue was dissolved in DCM, washed with
water, brine, and dried over Na2SO4. After removal of solvent under reduced pressure, the
residue was purified by flash column chromatography (hexane:EtOAc = 9:1) to afford the
title compound 17 (245 mg, 95%). 1H NMR (400 MHz, CDCl3) δ 4.29–4.18 (m, 3H), 3.74
(ddd, J = 6.2, 8.4, 11.2, 1H), 3.61–3.48 (m, 2H), 1.39 (d, J = 0.9, 3H), 1.32 (d, J = 5.0, 3H),
1.29 (t, J = 7.1, 3H). 13C NMR (126 MHz, CDCl3) δ 166.54, 107.70, 107.67, 72.67, 70.55,
69.89, 64.82, 60.53, 59.86, 24.94, 23.58, 12.37. MS (ESI) calculated for C11H19N3O5, m/z
273.13, found 296.14 (M+Na) +.
Synthesis of compound 18 (ethyl 2-(tert-butoxycarbonylamino)-3-(((S)2,2-dimethyl-1,3-
dioxolan-4-yl)methoxy)propanoate)
Reduction of the azide to the amine under Staudinger conditions.67 To 17 (230 mg, 0.84
mmol) dissolved in THF (8 mL) and H2O (30.3 mg, 1.68 mmol) was added PPh3 (265 mg,
1.01 mmol). The reaction mixture was refluxed for 6 h. After removal of solvent, the
reaction residue was dissolved in anhydrous DCM (5 mL) and di-tert-butyl dicarbonate
(Boc2O; 551 mg, 2.52 mmol) and TEA (351 μL, 2.52 mmol) was added and stirred at r.t. for
8h. The solvent was removed under vacuum and the residue was purified by flash column
chromatography (hexane:EtOAc = 17:3) to afford the title compound 18 (272 mg, 93%). 1H
NMR (400 MHz, CDCl3) δ 5.37 (t, J = 8.2, 1H), 4.42–4.32 (m, 1H), 4.26–4.13 (m, 3H),
3.99 (dd, J = 6.4, 8.3, 1H), 3.94–3.86 (m, 1H), 3.75–3.63 (m, 2H), 3.55–3.40 (m, 2H), 1.43
(s, 9H), 1.38 (d, J = 1.9, 3H), 1.33 (d, J = 0.6, 3H), 1.25 (t, J = 7.1, 3H). 13C NMR (126
MHz, CDCl3) δ 168.21, 153.15, 107.09, 77.59, 70.07, 69.60, 69.36, 64.18, 59.17, 51.70,
25.95, 24.32, 23.02, 11.81. MS (ESI) calculated for C16H29NO7, m/z 347.19, found 370.28
(M+Na) +.
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Syntheses of compounds 19a ((S)-methyl 3-tert-butoxy-2-(2-(tert-butoxycarbonylamino)-3-
(((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propanamido)propanoate) and 19b ((R)-
methyl 3-tert-butoxy-2-(2-(tert-butoxycarbonylamino)-3-(((S)-2,2-dimethyl-1,3-dioxolan-4-
yl)methoxy)propanamido)propanoate)
De-esterification of the ethyl ester of 18 and subsequent coupling to H-L- and -D-Ser(tBu)-
OMe3HCl were performed as described for the syntheses of compounds 12a-d to yield 19a
and 19b, respectively (70–75%).
19a—1H NMR (400 MHz, CDCl3) δ 7.21 (s, 1H), 5.48 (s, 1H), 4.71–4.62 (m, 1H), 4.25 (dt,
J = 5.9, 11.7, 2H), 4.06–3.98 (m, 1H), 3.89 (ddd, J = 2.4, 4.0, 9.5, 1H), 3.82–3.68 (m, 5H),
3.66–3.50 (m, 4H), 1.44 (s, 9H), 1.40 (d, J = 2.4, 3H), 1.33 (d, J = 2.2, 3H), 1.15–1.08 (m,
9H). 13C NMR (126 MHz, CDCl3) δ 168.88, 168.87, 168.81, 108.18, 73.14, 62.15, 71.24,
71.00, 69.90, 65.30, 65.06, 60.56, 51.78, 51.03, 28.38, 26.98, 25.97, 25.43, 24.10. MS (ESI)
calculated for C22H40N2O9, m/z 476.27, found 499.19 (M+Na) +.
19b—1H NMR (400 MHz, CDCl3) δ 7.21 (s, 1H), 5.49 (s, 1H), 4.66 (ddd, J = 3.2, 7.2, 11.3,
1H), 4.25 (ddd, J = 5.7, 11.6, 17.0, 2H), 4.06–3.98 (m, 1H), 3.89 (ddd, J = 2.4, 4.0, 9.5, 1H),
3.84–3.76 (m, 1H), 3.75–3.67 (m, 4H), 3.64–3.50 (m, 4H), 1.44 (s, 9H), 1.42–1.38 (m, 3H),
1.36–1.31 (m, 3H), 1.13–1.08 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 167.90, 167.83,
107.19, 72.16, 71.16, 70.27, 70.03, 68.94, 64.32, 64.09, 59.58, 50.80, 50.05, 27.40, 26.00,
24.99, 24.46, 23.12. MS (ESI) calculated for C22H40N2O9, m/z 476.27, found 499.19 (M
+Na) +.




Acetonide deprotection and O-palmitoylation were performed as described earlier (see
syntheses of 13a-d). 20a or 20b were obtained in 80–83% yield.
20a—1H NMR (400 MHz, CDCl3) δ 7.11 (t, J = 8.3, 1H), 5.40 (s, 1H), 5.16 (dd, J = 3.3,
5.5, 1H), 4.66 (tt, J = 3.0, 8.8, 1H), 4.38–4.22 (m, 2H), 4.18–4.06 (m, 1H), 3.96–3.76 (m,
2H), 3.71 (d, J = 1.5, 3H), 3.66–3.49 (m, 4H), 2.28 (dd, J = 7.7, 15.5, 4H), 1.58 (d, J = 5.7,
4H), 1.44 (s, 9H), 1.23 (s, 48H), 1.13–1.08 (m, 9H), 0.85 (t, J = 6.8, 6H). 13C NMR (126
MHz, CDCl3) δ 172.18, 171.88, 169.40, 168.79, 154.25, 79.11, 72.29, 69.96, 69.69, 68.70,
68.63, 68.58, 68.55, 68.48, 68.44, 68.41, 61.19, 60.94, 51.90, 51.66, 51.17, 33.06, 32.91,
30.74, 28.52, 28.48, 28.32, 28.18, 18.12, 27.94, 27.11, 26.09, 23.70, 21.51, 12.94. MS (ESI)
calculated for C51H96N2O11, m/z 912.70, found 935.54 (M+Na) +.
20b—1H NMR (400 MHz, CDCl3) δ 7.11 (t, J = 9.0, 1H), 5.40 (s, 1H), 5.23–5.11 (m, 1H),
4.66 (tt, J = 3.0, 8.6, 1H), 4.30 (ddd, J = 4.3, 10.2, 15.3, 2H), 4.11 (ddt, J = 5.0, 6.0, 10.3,
1H), 3.91–3.76 (m, 2H), 3.71 (d, J = 1.3, 3H), 3.68–3.49 (m, 4H), 2.28 (dd, J = 7.8, 15.5,
4H), 1.58 (dd, J = 6.9, 12.8, 4H), 1.44 (s, 9H), 1.23 (s, 48H), 1.14–1.07 (m, 9H), 0.85 (t, J =
6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 171.84, 171.56, 168.96, 168.46, 153.92, 78.72,
71.96, 69.62, 69.40, 68.37, 68.30, 68.25, 68.22, 68.15, 68.08, 60.86, 60.31, 51.57, 51.32,
50.84, 32.74, 32.58, 30.41, 28.19, 28.15, 27.99, 27.85, 27.79, 27.62, 26.78, 25.72, 23.38,
21.18, 12.61. MS (ESI) calculated for C51H96N2O11, m/z 912.70, found 935.54 (M+Na) +.
Syntheses of compound 21a ((S)-3-(2-amino-3-((S)-3-hydroxy-1-methoxy-1-oxopropan-2-
ylamino)- 3-oxopropoxy)propane-1,2-diyl dipalmitate; trifluoroacetate) and 21b ((S)-3-(2-
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One-step deprotection of the N-Boc and O-tBu groups utilizing TFA was carried out as
described earlier (syntheses of 14a-d). Title compounds were obtained as white glassy solids
21a or 21b (99–100%).
21a—1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 8.03 (d, J = 28.1, 1H), 5.28 (s, 1H), 5.15
(s, 1H), 4.71 (dd, J = 69.3, 103.2, 2H), 4.17 (ddd, J = 7.3, 17.4, 18.6, 2H), 4.06–3.81 (m,
3H), 3.76 (d, J = 14.3, 3H), 3.58 (dd, J = 10.2, 15.7, 2H), 2.28 (dd, J = 7.3, 11.9, 4H), 1.56
(s, 4H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 172.76, 172.47,
172.41, 172.34, 168.73, 68.50, 68.31, 68.22, 67.59, 61.22, 61.10, 60.49, 54.08, 53.97, 51.92,
51.63, 51.47. 32.90, 32.78, 30.63, 28.42, 28.37, 28.24, 28.08, 28.02, 27.85, 27.80, 23.55,
21.40, 12.82. MS (ESI) calculated for C42H80N2O9, m/z 756.59, found 757.45 (M+H) +.
21b—1H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 8.04 (s, 1H), 5.28 (s, 1H), 5.15 (s, 1H),
4.58 (d, J = 51.7, 2H), 4.18 (d, J = 42.7, 2H), 3.90 (s, 3H), 3.76 (d, J = 14.5, 3H), 3.59 (s,
2H), 2.28 (dd, J = 7.4, 11.7, 4H), 1.56 (s, 4H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 6H). 13C NMR
(126 MHz, CDCl3) δ 172.11, 171.82, 171.76, 171.69, 168.06, 67.84, 67.64, 67.55, 66.89,
60.55, 60.41, 59.84, 53.42, 53.32, 51.27, 50.98, 50.82, 32.24, 32.14, 29.97, 27.76, 27.72,
27.58, 27.42, 27.35, 27.19, 27.14, 22.89, 20.74, 12.16. MS (ESI) calculated for
C42H80N2O9, m/z 756.59, found 757.45 (M+H) +.
Synthesis of compound 22 ((S)-4-(benzyloxymethyl)-2,2-dimethyl-1,3-dioxolane)
O-benzylation of 1a was performed by first adding sodium hydride (NaH; 60% in mineral
oil, 363 mg) to a solution of (S)-(+)-2,2-dimethyl-1,3-dioxolane-4-methanol (1a, 200 mg,
1.51 mmol) in anhydrous DMF (5 mL) on ice. After stirring for 10 min, benzyl bromide
(BnBr; 360 μL, 3.03 mmol) was added slowly to the reaction mixture. The reaction was
brought to r.t. after 30 min and stirred for an additional 8 h. NaH was quenched by slowly
adding methanol to the reaction vessel at 0 °C. After removal of solvent, the residue was
dissolved in DCM and washed with water (1X) and the resulting water layer was extracted
with DCM (3X). The combined DCM layers were washed with brine and dried over
Na2SO4. After removal of solvent, the residue was purified by flash column chromatography
(hexane:EtOAc = 19:1) to yield the title compound 22 (330 mg, 98%). 1H NMR (400 MHz,
CDCl3) δ 7.36–7.30 (m, 4H), 7.29–7.24 (m, 1H), 4.62–4.51 (m, 2H), 4.33–4.25 (m, 1H),
4.04 (dd, J = 6.4, 8.3, 1H), 3.73 (dd, J = 6.3, 8.3, 1H), 3.54 (dd, J = 5.7, 9.8, 1H), 3.46 (dd, J
= 5.5, 9.8, 1H), 1.40 (s, 3H), 1.35 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 136.87, 127.39,
126.73, 126.71, 108.39, 73.68, 72.47, 70.00, 65.81, 25.74, 24.35. MS (ESI) calculated for
C13H18O3, m/z 222.13, found 245.13 (M+Na)+.
Synthesis of compound 23 ((R)-((2,3-bis(hexadecyloxy)propoxy)methyl)benzene)
Deprotection of the acetonide protecting group of 22 was achieved by stirring the compound
(180 mg, 0.81 mmol) in 70% acetic acid (AcOH:H2O = 7:3) as described for the syntheses
of 4a and 4b. After complete removal of acetic acid and water under reduced pressure, the
residue was dissolved in DMF (5 mL) and cooled to 0 °C. The resulting diol was O-
alkylated with 1-iodohexadecane (1.14g, 3.24 mmol) in the presence of NaH (60 % in
mineral oil, 770 mg) in anhydrous DMF (8 mL) at 0 °C. The reaction mixture was stirred for
30 min at 0 °C and the temperature was then raised to r.t. for 8 h. The excess NaH was
quenched by slowly adding methanol to the reaction at 0 °C. After removal of solvent, the
residue was dissolved in DCM and washed with water (1X). And the resulting water layer
was extracted with DCM (3X). The combined DCM layers were washed with brine and
dried over Na2SO4. After removal of solvent under vacuum, the residue was purified by
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flash column chromatography (hexane:EtOAc = 49:1) to afford a white solid (470 mg,
92%). 1H NMR (400 MHz, CDCl3) δ 7.31 (d, J = 4.3, 4H), 7.28–7.24 (m, 1H), 4.54 (s, 2H),
3.62–3.44 (m, 7H), 3.41 (t, J = 6.7, 2H), 1.60–1.47 (m, 4H), 1.26 (d, 52H), 0.86 (t, J = 6.8,
6H). 13C NMR (126 MHz, CDCl3) δ 138.42, 128.31, 127.58, 77.88, 73.34, 71.66, 70.79,
70.62, 70.24, 31.93, 30.09, 29.72, 29.66, 29.52, 29.38, 26.10, 22.70, 14.14. MS (ESI)
calculated for C42H78O3, m/z 630.60, found 653.61 (M+Na)+.
Synthesis of compound 24 ((R)-2,3-bis(hexadecyloxy)propyl 4-methylbenzenesulfonate)
O-debenzylation followed by O-tosylation of 23 en route to the iodo intermediate 25 was
obtained as follows: Hydrogenolysis of 23 (500 mg, 0.79 mmol) dissolved in a mixture of 20
mL MeOH/DCM (1:1) was carried out using Pd(OH)2/C (500 mg) and H2 at 55 psi in a Parr
apparatus for 8 h. The catalyst was removed by filtration over celite, and the solvent was
removed to afford the O-debenzylated intermediate as a white solid (425 mg, ~100%). After
drying completely, the solid was dissolved in anhydrous CH3CN (15 mL), followed by
addition of pyridine (320 μL, 3.96 mmol) and a catalytic amount of DMAP. Then p-TsCl
(755 mg, 3.96 mmol) was added and the reaction mixture was heated at 70 °C for 12 h. After
removal of solvent under vacuum, the residue was purified by flash column chromatography
(hexane:EtOAc = 17:1) to afford the title compound 24 (527 mg, 96%). 1H NMR (400 MHz,
CDCl3) δ 7.77 (d, J = 8.2, 2H), 7.31 (d, J = 8.5, 2H), 4.13 (dd, J = 4.1, 10.3, 1H), 4.00 (dd, J
= 5.8, 10.3, 1H), 3.62–3.54 (m, 1H), 3.47–3.41 (m, 2H), 3.38 (t, 2H), 3.33 (t, J = 6.7, 2H),
2.42 (s, 3H), 1.45 (s, 4H), 1.23 (s, 52H), 0.86 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3)
δ 143.66, 131.93, 128.75, 126.98, 75.16, 70.75, 69.80, 68.64, 68.30, 30.91, 28.85, 28.69,
28.65, 28.63, 28.60, 28.50, 28.46, 28.44, 28.35, 25.01, 24.94, 21.68, 20.62, 13.11. MS (ESI)
calculated for C42H78O5S, m/z 694.56, found 717.52 (M+Na)+.
Synthesis of compound 25 ((R)-1-(1-(hexadecyloxy)-3-iodopropan-2-yloxy)hexadecane)
The O-tosyl derivative 24 was converted to the iodo derivative 25. Iodine (310 mg, 12.23
mmol) and potassium iodide (KI; 2.03 g, 12.23 mmol) were added to a solution of 25 (850
mg, 1.22 mmol) in anhydrous DMF (15 mL) and the reaction was stirred at 80 °C for 24 h.
After removal of DMF under vacuum, the residue was diluted with DCM and washed with
water (1X), brine (1X) and dried over Na2SO4. The solvent was removed and the residue
was purified by flash column chromatography (hexane:EtOAc = 49:1) to yield the title
compound 25 (700 mg, 88%). 1H NMR (400 MHz, CDCl3) δ 3.51 (m, 3H), 3.45–3.39 (m,
3H), 3.37–3.24 (m, 3H), 1.60–1.50 (m, 4H), 1.23 (s, 52H), 0.86 (t, J = 6.9, 6H). 13C NMR
(126 MHz, CDCl3) δ 76.40, 70.86, 70.73, 69.25, 30.91, 28.91, 28.69, 28.66, 28.65, 28.61,
28.45, 28.43, 28.35, 25.09, 25.07, 21.68, 13.11, 6.39. MS (ESI) calculated for C35H71IO2,
m/z 650.45, found 673.42 (M+Na)+.
Synthesis of compound 26 ((6R,10R)-methyl 10-(hexadecyloxy)-2,2-dimethyl-4-oxo-3,12-
dioxa-8-thia-5-azaoctacosane-6-carboxylate)
S-alkylation ofBoc- L-Cys-OMe with 25 was carried out as follows: Boc-L-Cys-OMe (752
mg, 3.20 mmol) and TEA (445 μL, 3.20 mmol) were added to the solution of 25 (260 mg,
0.40 mmol) in anhydrous DMF (8 mL). The reaction was stirred at 85 °C for 2h. After
removal of DMF under vacuum, the residue was purified by flash column chromatography
(hexane:EtOAc = 19:1) to afford the title compound 26 (291 mg, 96%). 1H NMR (500 MHz,
CDCl3) δ 5.53 (d, J = 8.0, 1H), 4.51 (s, 1H), 3.73 (s, 3H), 3.48 (m, 5H), 3.40 (m, 6.7, 2H),
3.07–2.93 (m, 2H), 2.75 (dd, J = 4.9, 13.7, 1H), 2.63 (dd, J = 6.0, 13.7, 1H), 1.57–1.49 (m,
4H), 1.42 (s, 9H), 1.31–1.20 (m, 52H), 0.85 (t, J = 7.0, 6H). 13C NMR (126 MHz, CDCl3) δ
170.63, 154.23, 28.97, 77.55, 70.68, 70.28, 69.55, 52.47, 51.47, 34.44, 33.51, 30.90, 28.97,
28.69, 28.64, 28.35, 27.28, 25.08, 25.05, 21.68, 13.13. MS (ESI) calculated for C44H87O6S,
m/z 757.63, found 780.61 (M+Na)+.
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Synthesis of compound 27 ((5S,8R,12R)-methyl 8-(tert-butoxycarbonylamino)-12-
(hexadecyloxy)- 2,2-dimethyl-7-oxo-3,14-dioxa-10-thia-6-azatriacontane-5-carboxylate)
Compound 26 was obtained as a viscous oil (228 mg, 64%) via procedures similar to those
described for the syntheses of compounds 12a-d. 1H NMR (500 MHz, CDCl3) δ 5.60 (s,
1H), 4.64 (d, J = 8.1, 1H), 4.30 (s, 1H), 3.79 (dd, J = 3.0, 9.1, 1H), 3.71 (s, 3H), 3.60–3.47
(m, 7H), 3.45–3.35 (m, 2H), 2.95 (dd, J = 5.8, 13.9, 1H), 2.87 (dd, J = 6.9, 13.8, 1H), 2.78
(s, 2H), 1.58–1.49 (m, 4H), 1.43 (s, 6H), 1.30–1.20 (m, 52H), 1.11 (s, 8H), 0.85 (t, J = 7.0,
6H). 13C NMR (126 MHz, CDCl3) δ 169.58. 169.46, 154.24, 77.23, 72.40, 70.68, 70.27,
69.54, 60.72, 52.13, 51.33, 34.57 33.34, 30.90, 28.95, 28.69, 28.64, 28.62, 28.50, 28.35,
27.28, 26.26, 25.08, 25.03, 21.68, 13.13. MS (ESI) calculated for C51H100N2O8S, m/z
900.72 found 923.69 (M+Na)+.
Synthesis of compound 28 ((S)-methyl 2-((R)-2-amino-3-((R)-2,3-
bis(hexadecyloxy)propylthio)propanamido)-3-hydroxypropanoate; trifluoroacetate)
N-Boc deprotection with neat TFA was performed as described for the synthesis of 6a and
6b. 1H NMR (400 MHz, CDCl3) δ 8.30 (s, 1H), 4.64 (s, 1H), 4.32 (s, 1H), 4.00–3.82 (m,
1H), 3.74 (s, 3H), 3.61–3.48 (m, 3H), 3.47–3.37 (m, 3H), 3.18–3.07 (m, 1H), 3.01–2.89 (m,
1H), 2.86–2.66 (m, 1H), 1.59–1.47 (m, 4H), 1.23 (s, 48H), 0.86 (t, J = 6.8, 6H). 13C NMR
(126 MHz, CDCl3) δ 170.05, 77.85, 71.80, 71.12, 70.91, 61.75, 55.32, 53.06, 52.74, 34.98,
34.32, 31.93, 29.73, 29.68, 29.55, 29.51, 29.42, 29.38, 26.06, 25.87, 22.69, 14.12. MS (ESI)
calculated for C42H84N2O6S, m/z 744.61 found 645.61 (M+H)+.
Synthesis of compound 30 ((R)-methyl 3-hydroxy-2-palmitamidopropanoate)
N-palmitoylation of 29 was carried out as follows: H-D-Ser-OMe•HCl (29) was N-acylated
by first generating the free-base by the addition of 10 mL of sat. aqueous NaHCO3 solution
to a solution of 29 (200 mg, 1.04 mmol, Bachem) in EtOAc (10 mL), and then adding
palmitoyl chloride (377 μL, 1.24 mmol) dropwise to the reaction. The reaction mixture, after
stirring for 1 h, was extracted with EtOAc (3X). The combined EtOAc layers were washed
with brine and dried over Na2SO4. After removal of solvent under vacuum, the residue was
purified by flash column chromatography (hexane:EtOAc = 7:3) to afford the title
compound as a white solid (286 mg, 77%). 1H NMR (500 MHz, CDCl3) δ 6.61 (s, 1H),
4.65–4.58 (m, 1H), 3.92 (dd, J = 3.6, 11.1, 1H), 3.83 (d, J = 11.1, 1H), 3.73 (s, 3H), 2.25–
2.18 (m, 3H), 1.64–1.54 (m, 2H), 1.27–1.18 (m, 24H), 0.83 (t, J = 6.9, 3H). 13C NMR (126
MHz, CDCl3) d173.98, 171.65, 63.23, 54.59, 52.68, 36.48, 31.82, 29.70, 29.67, 29.66,
29.64, 29.52, 29.37, 29.36, 29.26, 25.59, 22.69, 14.12. MS (ESI) calculated for C20H39NO4,
m/z 357.29, found 358.30 (M+H)+ and 380.28 (M+Na)+.
Synthesis of compound 31 ((R)-methyl 2,2-dimethyl-3-palmitoyloxazolidine-4-carboxylate)
Compound 30 was acetonide protected with 2,2-dimethyoxypropane (2,2-DMP; 24 mL,
195.8 mmol) and pyridinium p-toluenesulfonate (PPTS; 281 mg, 1.12 mmol) by adding the
above reagents to compound 30 (2.0 g, 5.59 mmol) in toluene (25 mL), and the reaction
refluxed at 90 °C for 22 h. After concentrating under reduced pressure, the residue was
purified by flash column chromatography (hexane:EtOAc = 9:1) to afford the title
compound as a white solid (2.0 g, 90%). 1H NMR (500 MHz, CDCl3) δ 4.42 (dd, J = 1.3,
6.3, 1H), 4.20 (dd, J = 1.4, 9.3, 1H), 4.14 (dd, J = 6.3, 9.3, 1H), 3.78 (s, 3H), 2.18–2.03 (m,
2H), 1.67 (s, 2H), 1.63–1.57 (m, 2H), 1.54 (s, 3H), 1.28–1.20 (m, 24H), 0.85 (t, J = 7.0,
3H). 13C NMR (126 MHz, CDCl3) δ 171.15, 170.17, 96.62, 66.99, 59.49, 52.89, 35.64,
31.93, 29.70, 29.66, 29.64, 29.56, 29.48, 29.37, 29.25, 25.15, 24.57, 23.57, 22.70, 14.13. MS
(ESI) calculated for C23H43NO4, m/z 397.59, found 398.33 (M+H)+ and 420.31 (M+Na)+.
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Synthesis of compound 32 ((S)-1-(4-(hydroxymethyl)-2,2-dimethyloxazolidin-3-
yl)hexadecan-1-one)
The ester functional group of 31 was reduced to the primary alcohol by first diluting lithium
borohydride (LiBH4; 2.0 M in THF, 1.89 mL, 3.77 mmol) in 5 mL of THF (5 mL) cooled to
0°C for 30 min. Comound 31 (500 mg, 1.26 mmol), dissolved in THF (5 mL) was then
added dropwise, after which the reaction was stirred at 0 °C for 3 h and then maintained at
r.t. for an additional 6 h. After quenching the unreacted LiBH4 with water, the reaction
mixture was extracted with EtOAc (3X) and the combined EtOAc layers were washed by
brine and dried over Na2SO4. The solvent was removed under vacuum and the resulting
residue was purified by flash column chromatography (hexane:EtOAc = 4:1) to yield a white
solid (489 mg, 81%). 1H NMR (500 MHz, CDCl3) δ 4.40 (s, 1H), 4.04 (d, J = 9.0, 1H),
4.01–3.88 (m, 2H), 3.64 (d, J = 10.5, 2H), 2.39–2.26 (m, 2H), 1.62 (s, 2H), 1.59 (d, J = 17.8,
4H), 1.52 (s, 2H), 1.25 (d, J = 22.7, 24H), 0.86 (t, J = 6.9, 3H). 13C NMR (126 MHz,
CDCl3) δ 170.41, 95.27, 65.43, 62.93, 58.55, 35.49, 31.94, 29.71, 29.68, 29.65, 29.54,
29.38, 26.83, 25.20, 22.93, 22.71, 14.15. MS (ESI) calculated for C23H43NO4, m/z 369.58,
found 370.33 (M+H)+, 392.31 (M+Na)+.
Synthesis of compound 33 ((R)-1-(4-(iodomethyl)-2,2-dimethyloxazolidin-3-yl)hexadecan-1-
one)
Compound 33 (151 mg, 97%) was obtained following the procedure described for the
synthesis of 9. 1H NMR (400 MHz, CDCl3) δ 4.17–4.10 (m, 2H), 4.03–3.96 (m, 1H), 3.26
(dd, J = 9.9, 11.4, 1H), 3.16 (dt, J = 2.5, 9.9, 1H), 2.34–2.16 (m, 2H), 1.67–1.62 (m, 3H),
1.53–1.46 (m, 3H), 1.39–1.16 (m, 26H), 0.86 (t, J = 6.9, 3H). MS (ESI) calculated for
C22H42INO2m/z 479.23, found 502.21 (M+Na)+.
General procedure for S-alkylation: Synthesis of compound 34 (methyl 2-(tert-
butoxycarbonylamino)-3-(((R)-2,2-dimethyl-3-palmitoyloxazolidin-4-
yl)methylthio)propanoate)
To a solution of 33 (300 mg, 0.63 mmol) in anhydrous DMF (8 mL) was added TEA (872
μL, 6.26mmol), followed by Boc-L-Cys-OMe (1.03 g, 4.38 mmol). The reaction solution
was stirred at 85°C for 2 h. After removal of DMF under vacuum, the residue was purified
by flash column chromatography (hexane:EtOAc = 9:1) to afford 34 as a viscous oil (356
mg, 97%). 1H NMR (400 MHz, CDCl3) δ 5.32–5.24 (m, 1H), 4.61–4.48 (m, 1H), 4.03 (d, J
= 9.2, 1H), 3.95–3.89 (m, 1H), 3.87–3.81 (m, 1H), 3.76 (s, 3H), 3.07–2.92 (m, 2H), 2.79–
2.63 (m, 2H), 2.36–2.17 (m, 2H), 1.70–1.58 (m, 6H), 1.43 (s, 9H), 1.36–1.17 (m, 27H), 0.86
(t, J = 6.9, 3H). 13C NMR (126 MHz, CDCl3) δ 171.10, 169.73, 155.02, 95.54, 80.37, 66.36,
57.42, 53.39, 52.79, 35.86, 35.49, 35.46, 31.92, 29.70, 29.69, 29.68, 29.66, 29.59, 29.37,
28.27, 26.96, 25.08, 22.90, 22.70, 14.15. MS (ESI) calculated for C31H158N2O6S, m/z
586.40, found 609.39 (M+Na)+.
Synthesis of compound 35 ((S)-methyl 3-tert-butoxy-2-((R)-2-(tert-butoxycarbonylamino)-3-
(((R)- 2,2-dimethyl-3-palmitoyloxazolidin-4-yl)methylthio)propanamido)propanoate)
Compound 34 (400 mg, 0.68 mmol) in 15 mL THF was de-esterified using procedures as
described for the syntheses of 12a-d with the exception that barium hydroxide octahydrate
(645 mg, 2.04 mmol, in 6 mL H2O at 60 °C, 1h), and not LiOH was used; we elected to use
the much milder Ba(OH)2 conditions in view of potential lability of the amide bond in 34.
Subsequent coupling to H-L-Ser(tBu)-OMe•HCl was carried out as described earlier for
12a-d. Compound 35 was obtained as a viscous oil (274 mg, 55%). 1H NMR (400 MHz,
CDCl3) δ 7.03 (d, J = 8.2, 1H), 5.40 (s, 1H), 4.63 (d, J = 8.2, 1H), 4.35–4.24 (m, 1H), 4.11–
4.02 (m, 1H), 3.96–3,87 (m, 2H), 3.81 (dd, J = 2.8, 9.1, 1H), 3.74–3.69 (m, 3H), 3.54 (dd, J
= 3.2, 9.1, 1H), 3.05–2.94 (m, 1H), 2.93–2.79 (m, 2H), 2.77–2.67 (m, 1H), 2.38–2.23 (m,
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2H), 1.61 (s, 5H), 1.53–1.48 (m, 3H), 1.31–1.20 (m, 24H), 1.12 (s, 9H), 0.85 (t, J = 6.8,
3H). 13C NMR (126 MHz, CDCl3) δ 173.80, 170.63, 170.51, 170.02, 95.57, 80.38, 73.69,
73.58, 66.43, 63.58, 61.68, 61.61, 57.45, 53.15, 52.50, 52.48, 51.49, 36.71, 35.40, 35.13,
34.94, 32.92, 31.93, 30.95, 29.69, 29.66, 29.65, 29.54, 29.52, 29.38, 29.37, 29.31, 28.32,
28.28, 27.30, 27.28, 26.96, 25.71, 25.16, 22.96, 22.70. MS (ESI) calculated for
C38H71N3O8S, m/z 729.50, found 752.48 (M+Na)+.
Synthesis of compound 36 ((5S,8R,12R)-methyl 8-(tert-butoxycarbonylamino)-2,2-
dimethyl-7,14-dioxo-12-(palmitoyloxymethyl)-3-oxa-10-thia-6,13-diazanonacosane-5-
carboxylate)
The general procedure of acetonide deprotection and subsequent O-palmitoylation described
earlier for the synthesis of 11 was utilized. The reaction residue was purified by flash
column chromatography (hexane:EtOAc = 3:1) to afford the intermediate as a colorless oil.
(203 mg, 80%). 1H NMR (500 MHz, CDCl3) δ 6.21 (d, J = 7.9, 1H), 5.56 (d, J = 6.7, 1H),
4.68–4.58 (m, 1H), 4.43–4.31 (m, 2H), 4.21 (dd, J = 5.0, 11.3, 1H), 4.08 (dd, J = 4.9, 11.3,
1H), 3.81 (dd, J = 3.0, 9.1, 1H), 3.72 (s, 3H), 3.55 (dd, J = 3.3, 9.1, 1H), 3.01 (dd, J = 5.5,
13.9, 1H), 2.91–2.79 (m, 2H), 2.75–2.64 (m, J = 5.4, 14.0, 1H), 2.35–2.26 (m, 2H), 2.23–
2.10 (m, 2H), 1.63–1.55 (br s, 4H), 1.43 (s, 6H), 1.30–1.19 (m, 52H), 1.14–1.10 (m, 8H),
0.85 (t, J = 7.0, 6H). 13C NMR (126 MHz, CDCl3) δ 173.90, 173.29, 170.59, 170.47,
155.40, 80.21, 73.57, 64.46, 61.65, 53.72, 53.14, 52.47, 48.83, 36.70, 34.12, 31.93, 29.71,
29.67, 29.55, 29.50, 29.46, 29.42, 29.37, 29.30, 29.27, 29.18, 28.31, 27.27, 25.65, 24.88,
22.70, 14.15. MS (ESI) calculated for C51H97N3O9S, m/z 927.69, found 950.68 (M+Na)+.
Synthesis of compound 37 ((R)-3-((R)-2-amino-3-((S)-3-hydroxy-1-methoxy-1-oxopropan-2-
ylamino)-3-oxopropylthio)-2-palmitamidopropyl palmitate; trifluoroacetate)
The previously described N-Boc/O-tBu deprotection procedure (see syntheses of 14a-d) was
used. The title compound was obtained as a flaky yellow solid (99%). 1H NMR (500 MHz,
CDCl3) δ 8.46 (s, 1H), 6.57 (s, 1H), 4.73–4.59 (m, 1H), 4.53–4.34 (m, 1H), 4.34–4.23 (m,
1H), 4.23–4.15 (m, 1H), 4.15–4.06 (br s, 1H), 4.03–3.84 (m, 2H), 3.79–3.67 (m, 3H), 3.21–
2.93 (m, 2H), 2.90–2.63 (m, 2H), 2.37–2.10 (m, 4H), 1.64–1.49 (m, 4H), 1.32–1.16 (m,
48H), 0.85 (t, J = 6.9, 6H). 13C NMR (126 MHz, CDCl3) δ 174.32, 170.36, 170.21, 64.40,
53.13, 52.76, 52.64, 50.29, 49.20, 36.61, 34.02, 31.94, 29.75, 29.73, 29.72, 29.70, 29.68,
29.60, 29.55, 29.38, 29.34, 29.28, 29.23, 29.20, 29.12, 25.70, 24.85, 24.78, 22.70, 14.13. MS
(ESI) calculated for C42H81N3O7S, m/z 771.58, found 772.59 (M+H)+ and 794.57 (M+Na)+.
Synthesis of compound 38 ((R)-methyl 2,2,11,11-tetramethyl-4,9-dioxo-3,10-dioxa-5,8-
diazadodecane-6-carboxylate)
D-2,3-diaminopropionic acid monohydrochloride (Sigma-Aldrich, 500 mg, 3.56 mmol) was
N-boc protected by Boc2O (2.33 g, 10.67 mmol) in the presence of TEA (1.49 mL, 10.67
mmol) in DCM (10 mL). After stirring at r.t. for 2 h, the solvent was removed under vacuum
and the residue was purified by silica flash chromatography (DCM:MeOH = 17:3). The free
carboxyl group of the intermediate was converted to methyl ester by dissolving it in
anhydrous DCM (10 mL), followed by sequential addition of EDCI (1.11 g, 5.81 mmol), 1-
hydroxybenzotriazole hydrate (HOBt; 785 mg, 5.81 mmol), TEA (810 μL, 5.81 mmol),
anhydrous MeOH (353 μL, 8.71 mmol) and a catalytic amount of DMAP. After stirring at
r.t. for 10 h, solvent was removed from the reaction under vacuum and the reaction residue
was dissolved in DCM, washed with water (1X), brine (1X) and dried over Na2SO4. The
residue was purified by silica flash chromatography (hexane:EtOAc = 22: 3) to afford the
title compound 38 (702 mg, 62%). 1H NMR (400 MHz, CDCl3) δ 5.40 (s, 1H), 4.82 (s, 1H),
4.32 (s, 1H), 3.73 (s, 3H), 3.56–3.40 (m, 2H), 1.44–1.39 (m, 18H). 13C NMR (126 MHz,
CDCl3) δ 171.30, 156.13, 155.41, 80.14, 79.85, 54.17, 52.65, 42.40, 30.95, 28.29, 28.28.
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MS (ESI) calculated for C14H26N2O6, m/z 318.18, found 341.17 (M+Na)+ and 659.35 (M
+M+Na)+.
Synthesis of compound 39 ((R)-tert-butyl 3-hydroxypropane-1,2-diyldicarbamate)
Sodium borohydride (NaBH4; 285 mg, 7.54 mmol) was added to a solution of 39 (600mg,
2.20mmol) for reducing the ester to the corresponding primary alcohol. We used NaBH4 as
an alternative to LiBH4 described in the synthesis of 32 with significantly better yields. The
reaction mixture was refluxed at 75 °C and then anhydrous methanol (3 mL) was added
dropwise over a period of 1 h. After refluxing for an additional 3 h, the reaction was
acidified to pH 2.0 with 1 M HCl and THF was removed under vacuum. The residue was
extracted with DCM (3X) and the combined DCM layers were washed with brine and dried
over Na2SO4. The residue was purified by silica flash chromatography (hexane:EtOAc =
3:1) to yield 39 as a colorless oil (525 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 5.10 (s,
1H), 4.97 (s, 1H), 3.76–3.45 (m, 4H), 3.41–3.16 (m, 2H), 1.58–1.36 (m, 18H). 13C NMR
(126 MHz, CDCl3) δ 157.75, 155.74, 80.41, 79.62, 61.56, 52.27, 40.12, 30.95, 28.36, 28.29.
MS (ESI) calculated for C13H16N2O5, m/z 290.18, found 313.18 (M+Na)+ and 603.37 (M
+M+Na)+.
Synthesis of compound 40 ((R)-tert-butyl 3-iodopropane-1,2-diyldicarbamate)
A procedure essentially identical to that described for the synthesis of 9 was followed;
however the reaction was carried out at 0 °C and then warming to r.t. instead of at 90 °C in
an effort to minimize side-reactions and improve yield. No significant improvements in
yield, unfortunately, were obtained. Compound 40 was obtained as a white solid (489 mg,
71%). 1H NMR (400 MHz, CDCl3) δ 5.30 (s, 1H), 4.83 (s, 1H), 3.62 (s, 1H), 3.44–3.21 (m,
4H), 1.46 (s, 18H). 13C NMR (126 MHz, CDCl3) δ 155.76, 154.44, 79.00, 50.54, 43.16
29.92, 27.31, 27.19, 7.69. MS (ESI) calculated for C13H25N2O4, m/z 400.09, found 423.09
(M+Na)+ and 823.18 (M+M+Na)+.
Synthesis of compound 41 ((6R,10R)-methyl 10-(tert-butoxycarbonylamino)-1,1,1-
trichloro-15,15-dimethyl-4,13-dioxo-3,14-dioxa-8-thia-5,12-diazahexadecane-6-carboxylate)
Orthogonal protection of the amines of the 2,3-diaminopropionic acid fragment, and of the
amine of the cysteine unit was necessary. We elected to utilize Troc-L-Cys-OMe, which was
obtained from L-cystine dimethylester (Sigma-Aldrich) as follows. 2,2,2-trichloroethyl
chloroformate (805 μL, 5.86 mmol) was slowly added to a stirring solution of L-cystine
dimethylester dihydrochloride (500 mg, 1.47 mmol) in anhydrous DCM (10 mL) and
pyridine (10 mL) cooled to 0 °C. The reaction was brought to r.t. and stirred for 8 h. After
removal of solvent under vacuum, the residue was purified by flash chromatography
(hexane:EtOAc = 4:1) to afford N-Troc cystine dimethylester as a white solid. The disulfide
bond of the N-Troc-protected cystine ester was reduced by dissolving the solid in THF (10
mL), and adding tributylphosphine (Bu3P; 542 μL, 2.20 mmol) and H2O (132 μL, 7.33
mmol). The reaction was stirred at r.t. for 2 h. After removal of solvent, the residue was
purified by flash column chromatography (hexane:EtOAc = 9:1) to afford the title
compound as a oil (410 mg, 90%). The characterization data for Troc-L-Cys-OMe (Scheme
6, step d) is provided in the Supporting Information. S- alkylation of Troc L-Cys-OMe with
40 was performed as described earlier for 26. Compound 41 was obtained as a mixture with
the oxidized N-Troc cystine dimethylester as ascertained by LC-MS and 1H NMR. The Rfs
of both components were virtually identical, rendering the isolation of 41 very difficult by
flash chromatography. Reverse-phase HPLC employing several solvent combinations also
did not yield good separations. We reasoned, however, that N-Troc cystine dimethylester
would be inert to both N-Boc deprotection and N-acylation conditions that were to follow
(see synthesis of 42 below). We therefore proceeded without further purification.
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Synthesis of compound 42 ((6R,10R)-methyl 1,1,1-trichloro-4,13-dioxo-10-palmitamido-3-
oxa-8-thia-5,12-diazaoctacosane-6-carboxylate)
A crude sample of 41 (200 mg, 0.34 mmol) was dissolved in excess dry TFA and stirred at
r.t. for 30 min to effect N-Boc deprotection on the 2,3-diaminopropionic acid fragment.
Excess TFA was removed by purging nitrogen. The resulting diamino intermediate was
coupled with palmitic acid (264 mg, 1.03 mmol) using EDCI (197 mg, 1.03 mmol), HOBt
(139 mg, 1.03 mmol) and TEA (287 mL, 2.06 mmol), and a catalytic amount of DMAP in
anhydrous DMF (8 mL). The reaction was stirred at 60 °C for 10 h. After DMF was
removed under reduced pressure, the residue was dissolved with DCM and washed with
water (1X), brine (1X) and dried over Na2SO4. The residue was purified by silica flash
chromatography (hexane:EtOAc = 39:11) to afford the title compound 42 (185 mg,
64%). 1H NMR (500 MHz, CDCl3) δ 6.90 (d, J = 6.5, 1H), 6.24–6.14 (m, 1H), 4.82–4.73
(m, 1H), 4.73–4.63 (m, 1H), 4.62–4.54 (m, 1H), 3.98 (br s, 1H), 3.76 (d, J = 4.3, 3H), 3.53–
3.43 (m, 1H), 3.41–3.30 (m, 1H), 3.12–2.97 (m, 2H), 2.92–2.78 (m, 2H), 2.57–2.43 (m, 1H),
2.23–2.09 (m, 4H), 1.63–1.50 (m, 4H), 1.22 (s, 48H), 0.85 (t, J = 6.9, 6H). 13C NMR (126
MHz, CDCl3) δ 173.07, 171.90, 168.27, 151.86, 92.87 72.24, 52.01, 50.44, 48.60, 34.42,
34.16, 32.08, 31.71, 29.48, 27.27, 27.24, 27.22, 27.10, 27.07, 26.92, 26.85, 23.17, 20.25,
11.69. MS (ESI) calculated for C42H78Cl3N3O6S, m/z 857.47, found 880.45, 881.45, 882.45
(M+Na+ with expected chlorine isotopic mass-spectral envelope).
Synthesis of compound 43 ((6R,10R)-methyl 2,2-dimethyl-4,13-dioxo-10-palmitamido-3-
oxa-8-thia-5,12-diazaoctacosane-6-carboxylate)
The base-labile N-Troc protecting group on the cysteine unit had to be converted to the N-
Boc derivative in order to carry out subsequent base-catalyzed de-esterfication step (see
synthesis of 44 below). Accordingly, 42 (350mg, 0.41 mmol) was dissolved in THF (3 mL)
and zinc dust (266 mg, 4.07 mmol), AcOH (15 mL) and H2O (1 mL) was added to the
reaction. After stirring at r.t. for 1 h, zinc was filtered on celite and the filtrate was
concentrated under reduced pressure. Reprotection with Boc2O was achieved by dissolving
the completely dried intermediate in DCM and the addition of Boc2O (444 mg, 2.04 mmol)
in the presence of TEA (284 μL, 2.04 mmol), and stirring the reaction mixture at r.t. for 1h.
After the solvent was removed, the residue was purified by silica flash chromatography
(hexane:EtOAc = 7:3) to yield the desired product 43 as a white solid (217 mg, 68%). 1H
NMR (400 MHz, CDCl3) δ 6.81 (s, 1H), 5.43 (s, 1H), 4.55 (s, 1H), 4.03 (s, 1H), 3.82–3.77
(m, 3H), 3.53 (s, 1H), 3.42 (s, 1H), 3.11–2.86 (m, 3H), 2.30–2.13 (m, 4H), 1.69–1.56 (m,
4H), 1.54–1.44 (m,7H), 1.27 (s, 48H). 13C NMR (126 MHz, CDCl3) δ 173.14, 141.89,
169.32, 169.22, 78.11, 72.52, 51.39, 50.52, 48.69, 48.31, 40.02, 39.64, 34.60, 34.46, 33.77,
33.19, 32.16, 29.76, 27.55, 27.52, 27.50, 27.38, 27.36, 27.21, 27.17, 27.14, 27.12, 26.13,
23.57, 23.50, 23.48, 23.37, 20.53. MS (ESI) calculated for C44H85N3O6S, m/z 783.62, found
806.61 (M+Na)+.
Synthesis of compound 44 ((5S,8R,12R)-methyl 8-(tert-butoxycarbonylamino)-2,2-
dimethyl-7,15-dioxo-12-palmitamido-3-oxa-10-thia-6,14-diazatriacontane-5-carboxylate)
De-esterification followed by serine coupling was carried out as described for the synthesis
of 35. (75%) 1H NMR (400 MHz, CDCl3) δ 6.91 (s, 1H), 6.52 (s, 1H), 5.52 (s, 1H), 4.68–
4.61 (m, 1H), 3.83–3.77 (m, 1H), 3.74–3.69 (m, 3H), 3.59–3.51 (m, 1H), 3.50–3.32 (m, 2H),
2.98–2.83 (m, 2H), 2.23–2.09 (m, 4H), 1.65–1.51 (m, 4H), 1.46–1.40 (m, 8H), 1.22 (s, 48H),
1.14–1.09 (m, 9H), 0.85 (t, J = 6.8, 6H). 13C NMR (126 MHz, CDCl3) δ 174.15, 173.17,
169.65, 169.56, 154.54, 79.12, 72.61, 60.69, 52.18, 51.40, 50.55, 41.27, 35.75, 35.61, 30.91,
29.92, 28.69, 28.66, 28.65, 28.54, 28.52, 28.39, 28.38, 28.35, 28.32, 28.30, 27.32, 27.29,
26.26, 24.76, 24.67, 21.67, 13.11. MS (ESI) calculated for C51H98N4O8S, m/z 926.71, found
949.70 (M+Na)+.
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Synthesis of compound 45 ((S)-methyl 2-((R)-2-amino-3-((R)-2,3-dipalmitamidopropylthio)-
propanamido)-3-hydroxypropanoate; trifluoroacetate)
Compound 45 was deprotected with TFA as described earlier. The title compounds were
obtained as a flaky yellow solid (99%). 1H NMR (500 MHz, CDCl3) δ 7.21–7.11 (m, 1H),
7.20–7.11 (m, 1H), 4.70–4.54 (m, 1H), 4.51–4.37 (m, 1H), 3.90 (s, 2H), 3.71 (s, 3H), 3.49–
3.35 (m, 1H), 3.33–3.22 (m, 1H), 3.21–3.01 (m, 1H), 2.80–2.53 (m, 1H), 2.15 (s, 3H), 1.53
(s, 3H), 1.25 (d, J = 21.5, 49H), 0.85 (t, J = 6.9, 6H). 13C NMR (126 MHz, CDCl3) δ
132.65, 131.11, 129.02, 68.37, 52.91, 38.92, 36.93, 36.56, 36.55, 32.15, 30.56, 30.37, 29.97,
29.88, 29.83, 29.76, 29.68, 29.60, 29.56, 29.54, 29.51, 29.47, 29.46, 29.13, 25.98, 25.86,
25.77, 23.94, 23.20, 22.92, 14.41, 14.34, 14.28, 11.17. MS (ESI) calculated for
C42H82N4O6S, m/z 770.60, found 771.60 (M+H)+.
NF-κB induction—The induction of NF-κB was quantified using HEK-Blue-2™ cells as
previously described by us.42 HEK-Blue™-2 cells (HEK293 cells stably transfected with
TLR2, MD2, CD14, and sAP) were from InvivoGen (San Diego, CA), and were maintained
in HEK-Blue™ Selection medium containing zeocin and normocin. Stable expression of
secreted alkaline phosphatase (sAP) under control of NF-κB/AP-1 promoters is inducible by
the TLR2 agonists, and extracellular sAP in the supernatant is proportional to NF-κB
induction. HEK-Blue-2 cells were incubated at a density of ~105 cells/ml in a volume of 80
μl/well, in 384-well, flat-bottomed, cell culture-treated microtiter plates until confluency
was achieved, and subsequently graded concentrations of stimuli. sAP was assayed
spectrophotometrically using an alkaline phosphatase-specific chromogen (present in HEK-
detection medium as supplied by the vendor) at 620 nm.
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TLR2 agonistic activities of the lipopeptide analogues. HEK293 cells stably transfected with
a TLR2-NF-κB-SEAP reporter gene was used in a 384 well format. Data points represent
means and sd determined on triplicate samples.
Wu et al. Page 27














TLR2 agonistic activities of the ether, monoamide and diamide lipopeptide analogues.
HEK293 cells stably transfected with a TLR2-NF-κB-SEAP reporter gene was used in a 384
well format. Data points represent means and sd determined on triplicate samples.
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Reagents and conditions: a: p-TsCl, pyr, DCM, 0 °C-r.t., 8 h;
b: N-Boc-2-aminoethanethiol, NaH, DMF, 0 °C-r.t., 8 h;
c: 70% AcOH, r.t., 12 h;
d: C15H31COCl, pyr, DMAP, DCM, 0 °C-r.t., 10 h;
e: TFA, r.t., 30 min;
f: Boc-L-Serine-OH, EDCI, EDIPA, DMAP, DCM, 0 °C-r.t., 8 h;
g: TFA, r.t., 30 min.
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Reagents and conditions: a: PPh3, I2, imidazole, toluene, 90 °C, 2 h;
b: Boc-L- or -D-Cys-OMe, TEA, DMF, 85°C, 4 h;
c: i) 70% AcOH, r.t., 24 h; ii) C15H31COCl, pyr, DMAP, DCM, 0 °C- r.t., 8 h; iii)TFA, r.t.,
30 min;
d: i) LiOH, THF/H2O, r.t., 10 h; ii) H-L-Ser(OtBu)-OtBu•HCl or H-L-Ser(OtBu)-OMe•HCl
or H-D-Ser(OtBu)-OMe•HCl, EDCI, EDIPA, DMAP, DCM, 0 °C-r.t., 8 h;
e: i) 70% AcOH, r.t.,12 h; ii) C15H31COCl, pyr, DMAP, DCM, 0 °C-r.t., 10 h;
f: TFA, r.t., 30 min.
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Reagents and conditions: a: Ethyl 2,3-epoxypropanoate, BF3•OEt2, DCM, r.t., 5 h;
b: p-TsCl, TEA, DCM, 0°C-r.t., 8 h;
c: NaN3, DMF, r.t., 12 h;
d: i) PPh3, H2O, THF, reflux, 6 h; ii) Boc2O, DCM, r.t., 8 h;
e: i) LiOH, THF/H2O, r.t., 10 h; ii) H-L-Ser(tBu)-OMe•HCl or H-D-Ser(t-Bu)-OMe•HCl,
EDCI, EDIPA, DMAP, DCM, 0°C-r.t., 8 h;
f: i) 70% AcOH, r.t., 12 h; ii) C15H31COCl, pyr, DMAP, DCM, 0°C-r.t., 10 h;
g: TFA, r.t., 30 min.
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Reagents and conditions: a: BnBr, NaH, DMF, 0 °C- r.t., 8 h;
b: i) 70% AcOH, r.t., 12 h; ii) C16H33I, NaH, DMF, 0 °C- r.t., 8 h;
c: i) Pd/C, H2, 8 h; ii) TsCl, pyr, DMAP, CH3CN, 70 °C, 12 h;
d: I2, KI, DMF, 80 °C, 24 h;
e: Boc-L-Cys-OMe, TEA, DMF, 85 °C, 2 h;
f: i) LiOH, THF/H2O, r.t., 10 h; ii) H-L-Ser(tBu)-OMe •HCl, EDCI, EDIPA, DMAP, DCM,
0 °C-r.t., 8 h;
g: TFA, r.t., 30 min.
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Reagents and conditions: a: C15H31COCl, aq.NaHCO3, EtOAc, r.t.,1 h;
b: 2,2-DMP, PPTS, toluene, 90 °C, 22 h;
c: LiBH4, THF, 0 °C(3h) - r.t.(6h);
d: PPh3, I2, toluene, 90 °C, 2 h;
e: Boc-L-Cys-OMe, TEA, DMF, 85 °C, 2 h;
f: i) Ba(OH)2, AcCN/H2O, 60 °C, 1 h; ii) H-L-Ser(tBu)-OMe·HCl, EDCI, EDIPA, DMAP,
DCM, 0°C- r.t., 8 h;
g: i) 70% AcOH, r.t.,12 h; ii) C15H31COCl, pyr, DMAP, DCM, 0 °C-r.t., 10 h;
h: TFA, r.t., 30 min.
Wu et al. Page 33














Reagents and conditions: a: i) (Boc)2O, TEA, DCM, r.t., 2 h; ii) MeOH, EDCI, HOBt, TEA,
DMAP, DCM, 10 h;
b: NaBH4, MeOH, THF, reflux, 4 h;
c: I2, PPh3, imidazole, DCM, 0 °C-rt, 2 h;
d: Troc-L-Cys-OMe, TEA, DMF, 85 °C, 2 h;
e: i) TFA, r.t., 30 min; ii) C15H31COOH, EDCI, HOBt, TEA, DMAP, DMF, 60 °C, 10 h;
f: i) Zn dust, AcOH, H2O, THF, r.t., 1 h; ii) (Boc)2O, TEA, DCM, r.t., 1 h;
g: i) Ba(OH)2, THF/H2O, 60 °C, 1 h; ii) H-L-Ser(tBu)-OMe•HCl, EDCI, HOBt, EDIPA,
DMAP, DMF, 60 °C, 10 h;
h: TFA, r.t., 30 min.
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